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ROLE OF CYCLOOXYGENASE-2 IN ABDOMINAL AORTIC ANEURYSMS IN 
MICE 
 
 
Abdominal aortic aneurysm (AAA) is a chronic inflammatory disease with no 
available pharmacological treatment. AAA formation reduces the structural integrity of 
the vessel and increases the susceptibility to rupture. The inflammatory response within 
human aneurysmal tissue is characterized by increased expression of cyclooxygenase-2 
(COX-2). Similarly, in a mouse model of the disease induced by chronic Angiotensin II 
(AngII) infusion, we have shown that COX-2 expression in the abdominal aortic smooth 
muscle layer increases early in the development of the disease. Furthermore, genetic or 
pharmacological inactivation of COX-2 prior to disease initiation reduces AAA 
incidence.  
The current study utilized nonhyperlipidemic mice to determine the effectiveness 
of COX-2 inhibition initiated after AAA formation. COX-2 inhibitor treatment was 
initiated 5 days after beginning the AngII infusion, a time-point where significant 
aneurysmal pathology is observed. COX-2 inhibition with celecoxib significantly reduced 
the incidence as well as severity of AAAs as compared to the control group. Celecoxib 
treatment also protected the mice from aortic rupture and death. AAA development is 
characterized by degradation of the aortic smooth muscle layer with loss of the 
contractile phenotype. We found that the effectiveness of celecoxib was associated with 
significantly increased mRNA expression of alpha-actin, SM22alpha and desmin, all of 
which are markers of a differentiated smooth muscle cell phenotype. Celecoxib treatment 
also decreased mRNA expression of a marker of dedifferentiated smooth muscle 
(hyaluronic acid synthase 2). We also examined the role of altered expression of COX-2 
in the increased susceptibility of the abdominal segment to AAA formation. We found a 
prolonged and greater induction of COX-2 in the abdominal aortic smooth muscle layer 
in contrast to a transient induction of COX-2 in the other regions of the aorta throughout 
disease progression. Overall, these findings suggest that COX-2 plays an important role 
in AAA development in mice, and COX-2 inhibition with celecoxib attenuates 
progression of aneurysm development by maintaining a differentiated phenotype in 
abdominal aortic smooth muscle cells. 
 
 
KEYWORDS: Abdominal aortic aneurysm (AAA), Cyclooxygenase-2 (COX-2), COX-2 
inhibitor, Celecoxib, Angiotensin II (AngII) 
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CHAPTER 1 
BACKGROUND 
1.1. ABDOMINAL AORTIC ANEURYSMS  
 
1.1.1. Epidemiology and natural history of abdominal aortic aneurysms 
Abdominal aortic aneurysms (AAAs) have emerged to be a major health concern 
throughout the world, particularly in the developing countries.[1] It is known to affect 
mostly the ageing population, and is the 10th leading cause of death in men over the age 
of 55 years.[2] AAA is a chronic vascular condition of the aorta involving an increase in 
diameter of at least 50% as compared to the expected normal diameter, and has 
potentially life-threatening implications.[3] It begins as minor vessel dilation that 
progress over years to produce a weakened aorta with increased susceptibility for 
rupture.[4] Ruptured AAAs have greater than a 90% incidence of mortality, resulting in 
approximately 15,000 deaths per year in the United States.[5, 6] Of particular concern is 
that, unlike coronary heart disease, the incidence of AAAs is reported to be increasing in 
the western countries.[7, 8] Moreover, although AAAs are thought to be responsible for 
approximately 2% of all deaths, these estimates of mortality are suggested to be 
hampered by attributing a portion of sudden deaths to cardiac failure rather than the 
actual cause of ruptured AAAs, because a pre-existing AAA had not been 
documented.[9]  
The diameter of the normal abdominal aorta in humans is approximately 2 cm. 
Thus, a person having an abdominal aortic diameter of ≥3 cm is considered to be 
diagnosed of an AAA.[10] The rate of aneurysmal growth has been found to be positively 
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correlated to the diameter of the AAA.[11] The smallest AAAs (3 cm – 3.5 cm in 
diameter) require approximately 5 years to attain a diameter of 5.5 cm, at which stage 
surgical intervention is suggested.[12] The average rate at which an AAA, which has a 
diameter of ≤ 5.5 cm, expands has been suggested to be 2.6 mm per year.[13] Moreover, 
the AAA diameter has been suggested to be the strongest predictor of rupture of the 
abdominal aorta. Lederle et al. have suggested that the rupture rates of AAAs measuring 
5.5 to 5.9, 6 to 6.9, and ≥ 7 cm are approximately 8%, 10% and 20% per year, 
respectively.[11] 
 
1.1.2. Risk factors for AAAs 
AAAs have been associated with a number of non-specific risk factors based on 
data collected from epidemiological screening studies. Of these, male gender and 
increasing age are probably the most prominent although non-modifiable risk factors for 
AAAs.[9] The incidence of AAAs is known to increase with increasing age in men. Thus, 
AAAs have a prevalence of approximately 1.3% in men 45 to 54 years of age which 
increases to approximately 5% in men 65 years or older. However, in men 75 to 84 years 
of age, the prevalence of AAAs is reported to be as high as 12.5%. In contrast, in the 
same age groups as above, the prevalence of AAAs in women was reported to be 0% in 
the youngest group and 5.2% in the oldest age group.[5, 14, 15]  
Tobacco smoking has been suggested to be the most important environmental risk 
factor for the development and progression of AAAs.[1] The prevalence of the disease in 
people smoking tobacco is known to be approximately 4 times more than those who have 
not smoked during their life.[16] The rate of growth of these aneurysms in current 
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smokers has also been reported to be 15 to 20% higher than that in non-smokers.[13] 
However, this risk has also been found to decrease gradually with termination of 
smoking.[17] Thus, the above reports suggest that smoking cessation should be one of the 
major priorities for patients with AAAs. 
AAA has been traditionally regarded as a consequence of atherosclerosis.[18] 
However, recent evidences suggest that the pathobiology associated with these two 
diseases are significantly different from each other, at least during the initial 
development.[19] While macrophages in atherosclerotic lesions are usually localized in 
the subintimal space, macrophages in AAAs are most often identified in the medial 
layer.[20] Brady et al., while reporting on the risk factors associated with AAAs during 
the UK Small Aneurysm Trial, have also shown that patients with the greatest 
atherosclerotic burden exhibit the slowest growth of AAAs.[13] In contrast, a recent 
study by Golledge et al. suggests that a low high-density lipoprotein level is likely one of 
the most sensitive predictors of AAAs.[21] Thus, with different studies reporting 
conflicting evidence, the role of atherosclerosis in the development of AAAs is not clear. 
Interestingly, diabetes mellitus, another cardiovascular risk factor, has been 
reported to be negatively associated with AAA growth. Patients with diabetes were found 
to have a 30% reduction in AAA growth, as compared to those without the disease.[13] 
The wall of the aorta has been shown to be thicker as the stress on the vascular wall is 
reduced in diabetic patients.[22] Moreover, it has been recently suggested that the 
glycation of extracellular matrix molecules such as collagen, that occurs during diabetes 
may increase the resistance of the aortic wall to proteolysis during aneurysmal 
degeneration and may contribute to a protective effect during AAA expansion.[23] 
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Family history is now widely accepted as a significant risk factor correlated with 
AAA development.[10, 20] At least 15% of people detected with AAAs were found to 
have first-degree family members with AAAs.[24] Ethnicity of the patients may also be 
important with evidence that the incidence of AAAs is more common in Northern 
Europeans than Asians or Africans.[10, 25] Finally, arterial hypertension was found to 
have only a minor impact on the incidence of AAAs. It should be noted however, that it 
is difficult to assess the correlation of blood pressure and AAA, as hypertension is 
usually defined on the basis of the patient receiving an anti-hypertensive medication.[9] 
Therefore, although the primary risk factors associated with AAA development, 
including advanced age, male gender and smoking show similarity to atherosclerosis, the 
majority of evidence suggests that the etiology of AAAs is distinct from other 
cardiovascular diseases. 
 
1.1.3. Pathobiology of AAAs 
AAAs are known to develop in the infrarenal region of the aorta i.e., just below 
the renal arteries. The major characteristic features during the pathogenesis of AAAs 
include chronic inflammation of the aortic wall, uncontrolled protease production leading 
to destructive remodeling of the vessel wall, and depletion of medial smooth muscle 
cells.[12] 
Alteration of the connective tissue in the aortic wall is a primary feature of AAA 
development in humans. The connective tissue is comprised mainly of elastin and 
collagen, which impart mechanical properties to the aorta. While the network of elastic 
fibers is responsible for the elastic properties of the aorta, collagen (types I and III) 
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provides tensile strength, and thereby maintains the structural integrity of the vessel 
wall.[1] AAA formation is characterized by significant elastin fragmentation as well as a 
decrease in the concentration of elastin.[26, 27] Thus, loss of elastin in the medial layer 
has been suggested to contribute primarily to the initial dilation of the aorta during AAA 
formation. In the absence of sufficient medial elastin necessary for providing structural 
integrity, collagen which is present mostly in the adventitial tissue is thought to be 
providing compensatory function for maintaining the resistance of the aorta. Thus, 
degradation of the adventitial collagen has been suggested to be the ultimate step leading 
to the rupture of the aorta.[28, 29]  
The proteolytic degradation within the aneurysmal wall is believed to be mediated 
by a variety of proteases which are produced by the medial smooth muscle cells, 
adventitial fibroblasts and the inflammatory infiltrate.[1] The most prominent among 
these are the matrix metalloproteinases (MMPs), especially MMP-2 and MMP-9. Various 
studies have reported the increased expression and activity of MMPs in the aortic wall 
during AAA development.[30, 31] Both MMP-2 and MMP-9 have elastolytic as well as 
collagenolytic activities. While MMP-2 is primarily active during the early expansion of 
non-ruptured AAAs, MMP-9 is less prevalent in the smaller aneurysms, and is believed 
to play a role in the continued expansion of AAAs during the advanced stages of the 
disease.[20] Both MMP-8 and MMP-9 have been reported to be increased at the site of 
aortic rupture.[32] Thus, in addition to their proteolytic activities, MMPs are also thought 
to regulate the arterial neovascularization important during AAA rupture.[20, 33, 34]  
Various cell types have been reported to be responsible for producing the 
enzymes necessary for AAA progression. These include mononuclear phagocytes, 
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activated tissue macrophages, vascular smooth muscle cells, adventitial fibroblasts, 
neutrophils and lymphocytes.[35] Moreover, the presence of T cells, B lymphocytes and 
dendritic cells in the cellular infiltrate also suggest the role of an immune response in 
AAAs.[36] More than 80% of human AAAs are reported to show histological evidence 
of inflammatory cell infiltration.[29] These include C-reactive protein, IL-1β, TNF-α and 
IL-6.[12, 37] In addition, COX-2 and resultant PGE2 have also been shown to be 
expressed in human aneurysmal tissues.[4, 38] Thus, inflammation is believed to play a 
crucial role in the development of AAAs. 
 
1.1.4. Diagnosis and management of AAAs 
AAA development and progression are known to be asymptomatic in most 
patients. Minor and non-specific symptoms include vague and chronic abdominal and 
back pain, and the diagnosis of an AAA is usually incidental while assessing other 
medical complaints. With few prognostic markers available, the most commonly used 
method to diagnose AAAs is ultrasonography. This procedure is one of the simplest and 
cheapest diagnostic tools for AAAs and is currently used for population screening and 
surveillance, pre-operative assessment, as well as post-operative evaluation of AAAs. 
Ultrasonography has been reported to effectively measure the internal aortic diameter in 
AAAs, with an accuracy of 2- 3 mm. In cases where ultrasound has identified expansion 
of the internal aortic diameter sufficient to warrant surgery, CT scans may also be utilized 
to aid in determining the specific form of surgery that is required.[1, 6, 35] Recently, new 
imaging techniques using computed tomography or magnetic resonance imaging or three-
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dimensional reconstruction have been suggested to provide information on wall tension 
or shear stress in AAAs for better prediction of the risk of aortic rupture.[39]  
Surgery is the only treatment option currently available for patients with 
AAAs.[6] The decision as to whether or not to operate is based on criteria that include the 
risk of rupture of the involved AAA, the risk of the surgical procedure itself, and the 
condition of the patient. Data from four randomized controlled trials that observed the 
expansion of small AAAs with an internal diameter of less than 5.5 cm show that the rate 
of rupture is approximately 0.5 – 1% per year, if surgery was performed when the 
diameter exceeded 5.5 cm. Moreover, the risk compared between the patients who 
underwent an early elective surgery versus those receiving late repair, was found to be 
similar.[40-44] Thus, regular surveillance of smaller AAAs without elective repair is 
considered to be safe, whereas surgery is reserved for the most severe cases where the 
diameter of the abdominal aorta exceeds 5.5 cm.[1] 
Two types of surgery are usually performed on AAA patients – open surgical 
treatment and endovascular insertion of vascular stents. The open surgery is usually 
associated with a high perioperative mortality rate of up to 5%, as well as an extended 
recovery time. Although endovascular repair may show improved perioperative 
morbidity as compared to open surgery, complications related to limited durability and 
requirements involving re-intervention and follow-up imaging for extended periods have 
raised questions about the value of the procedure.[40, 41, 44, 45] Thus, with significant 
risk and expense associated with surgery, together with the effectiveness of screening 
procedures that facilitate early detection of slow-growing small AAAs, there is a need to 
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identify effective pharmacological treatments which can attenuate or eliminate the growth 
of AAAs. 
 
1.1.5. Animal models of AAAs 
A number of experimental models of AAA formation have been developed which 
mimic the cellular and biochemical characteristics of the human disease. These models 
utilize a variety of methods including chemical induction or genetic manipulation to 
induce the disease.[46] While large animals have been used to develop novel methods for 
AAA surgery, small animal models, especially in rodents, have been developed to better 
understand the pathological characteristics of the disease and thereby discover new 
therapeutic treatments for AAAs.[47] The elastase perfusion and the CaCl2 induced AAA 
models have been the commonly used chemical induction models. The elastase perfusion 
model was initially developed in rats where Anidjar et al. showed that a 2 hour 
intraluminal perfusion of porcine pancreatic elastase resulted in complete loss of elastin 
in the involved aortic segment during the 3 weeks following the procedure.[48] The 
elastase perfusion model has also been adapted for use in mice.[49] The calcium chloride 
(CaCl2)  model uses a similar approach when gauze treated with CaCl2 is placed directly 
over the adventitial layer of the abdominal aorta for 10 minutes, which results in AAA 
formation within 2 to 4 weeks.[50] However, these models are not only technically 
challenging because they involve a major surgery and prolonged exposure to an 
anesthetic, but there is also concern for their ability to effectively mimic the chronic 
development of AAAs in humans.[47]  
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One of the most widely utilized animal models to study AAAs is the Angiotensin 
II (AngII) infusion model in mice. This model was originally developed by Daugherty et 
al. in apolipoprotein E (ApoE) -deficient hyperlipidemic mice, where chronic infusion of 
500 to 1000 ng/kg/min of AngII provided subcutaneously via osmotic mini-pumps was 
found to induce AAAs in these mice.[51] However, over the 28 day infusion period, 
AAAs were found to develop in the suprarenal region of the aorta, as opposed to the 
infrarenal AAAs observed in humans. Similarly, with the same dose of AngII infusion, 
AAAs were also observed in low-density lipoprotein receptor (Ldlr) –deficient mice as 
well.[52] The AngII-induced AAA model was found to display multiple characteristics of 
human AAAs and has provided mechanistic insight into the formation and progression of 
the disease.[53] Similar to the disease in humans, AngII-induced AAA development in 
mice is characterized by inflammatory cell infiltration into the aortic media, followed by 
remodeling of the vessel wall, and eventual medial degradation.[54] Previous studies 
suggested that only hyperlipidemic mouse strains, ApoE-deficient or Ldlr-deficient, had 
significant susceptibility to AngII-induced AAA development. However, studies in our 
laboratory have identified a nonhyperlipidemic C57BL6J/129Ola mixed background 
strain of mice that are as susceptible to AngII-induced AAAs as the hyperlipidemic 
strains.[55, 56] Thus, the ability to produce AAAs in a reproducible manner using the 
AngII infusion model in nonhyperlipidemic mice is advantageous, as it allows the study 
of the mechanisms of AAA development independent of an atherosclerotic burden that 
may indirectly affect the disease formation or progression. 
 
10 
 
1.1.5. Potential therapeutic strategies for AAAs 
Based on studies in animal models of AAAs, as well as human studies with AAA 
explants, association of AAAs with certain drugs and randomized controlled trials with 
AAA patients, a variety of strategies are currently being considered to treat AAAs.[9, 44] 
Smoking is considered the most important modifiable risk factor for AAAs.[1, 44] With 
the risk of AAAs shown to gradually decrease with smoking cessation, patients with 
AAAs are advised to stop smoking tobacco to allow for a decrease in the growth rate of 
the AAAs.[1, 13, 17] Studies using a rat AAA model have shown that reduced laminar 
flow in the abdominal aorta contributes to AAA expansion.[57] A recent study in humans 
using magnetic resonance imaging shows that exercise increases the abdominal aortic 
laminar blood flow in AAA patients, and thus could potentially limit AAA 
progression.[58] Thus, with exercise known to reduce other cardiovascular events, AAA 
patients are currently being advised to exercise regularly to improve hemodynamic 
laminar blood flow characteristics in the abdominal aorta.[44] 
Previous reports with animal models as well a limited number of human studies 
have suggested the beneficial effect of β-blockers in reducing AAA growth.[59, 60] 
However, 2 large randomized controlled trials have failed to show a significant effect of 
the β-blocker, propranolol on the growth rate of small AAAs.[44, 61] With the central 
role of MMPs in AAA development and rupture, several animal studies were carried out 
examining the role of protease inhibitors in limiting AAA expansion. Doxycycline, a 
synthetic tetracycline derivative, known to inhibit MMPs, has been shown to prevent 
aneurysmal growth in experimental AAAs.[62] Studies in humans have also shown 
doxycycline to effectively reduce the growth of small AAAs, as well as in AAA patient 
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that have undergone endovascular repair.[63-65] Thus, doxycycline shows promise for 
treating AAAs and two large randomized controlled trials are currently being performed 
to determine its efficacy in limiting the progression of small AAAs.[44] 
Several animal studies have suggested that the use of statins may be potentially 
beneficial in preventing AAA development.[66-68] However, in humans, there are 
conflicting reports on the efficacy of statins in reducing AAA growth.[69, 70] 
Angiotensin II (AngII) has also been well-known to play an important role in the 
development of AAAs in mice.[51] Inhibition of the Ang pathway, utilizing AngII 
receptor blockers or angiotensin converting enzyme inhibitors, has also been suggested to 
prevent AAA development in several animal studies.[71, 72] However, since no 
randomized controlled trials have been performed to determine the effect of statins or 
suppression of the AngII pathway in reducing AAA growth, the current role of these 
drugs as a potential therapeutic strategy for AAAs is uncertain.[44] 
Although a number of potential medications are being considered for limiting 
AAA progression, there is no current evidence which shows convincingly that any of 
these drugs can be effectively used to treat AAAs. Thus, regular surveillance of small 
AAAs until the disease progresses to a sufficiently large size to meet the criteria required 
for surgical repair seems to be the only therapeutic strategy currently in place for AAAs. 
 
 
 
 
 
 
12 
 
1.2. ANGIOTENSIN II AND THE CARDIOVASCULAR SYSTEM 
 
The renin-angiotensin system is well-known to play a vital role in the 
physiological and pathological responses of the cardiovascular system. Angiotensin II 
(AngII) is the key effector molecule of the renin-angiotensin system and affects the 
functionality of multiple organs including heart, kidney, brain and the vasculature. The 
classical pathway begins with the acid protease renin which is initially released from the 
juxtaglomerular cells of the kidney into the circulation. Renin thereafter cleaves 
angiotensinogen, synthesized by the liver, to produce the inactive decapeptide AngI. 
AngI is then cleaved by the angiotensin converting enzyme (ACE) to produce the active 
octapeptide AngII. All effectors of the renin-angiotensin system are also expressed 
locally in various tissues, and this local generation of AngII in the vasculature has been 
shown to be particularly important in regulating vascular inflammation.[73-75] 
The primary effect of AngII is in the regulation of vascular tone, blood pressure 
and electrolyte homeostasis.[73] In the vasculature, AngII has been shown to elicit 
vasoconstriction as well as hypertrophy of vascular smooth muscle cells.[76] One of the 
most well-defined characteristics of AngII is its mitogenic potential, whereby AngII 
increases proliferation of vascular smooth muscle cells.[77-79] AngII has also been 
shown to be a key regulator of vascular inflammation, by increasing vascular 
permeability, inducing leukocyte infiltration from the circulation into the perivascular 
space, as well as in tissue remodeling via regulation of cell growth and matrix 
synthesis.[75, 80] 
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AngII is known to mediate its effects by binding to two G-protein coupled 
receptors: angiotensin receptor type 1 (AT1 receptor) and angiotensin receptor type 2 
(AT2 receptor). These are typical polypeptide proteins with 7 trans-membrane domains. 
Most of the known pathophysiological effects of AngII, including vasoconstriction, cell 
growth and proliferation, vascular inflammation, stimulation of aldosterone synthesis and 
retention of salt and water are mediated via the AT1 receptors. The AT1 receptors are 
present in various tissues and organs throughout the body including blood vessels, heart, 
lung, liver, adrenals, kidney and the brain. While humans possess only one subtype of the 
AT1 receptor, rodents express 2 subtypes of the receptor, including AT1a and AT1b, 
which are known to share 95% sequence homology.[73-75, 81] Although similar, the 
AT1a receptor has been shown to be more important than the AT1b receptor in regulating 
blood pressure in the vasculature of mice.[82] The expression of AT1 receptors is 
regulated by a negative feedback control from its agonist, AngII. While an acute 
stimulation by AngII leads to increased AT1 receptor activation, chronic exposure to 
AngII is known to down-regulate the receptor expression. The intracellular cytoplasmic 
tail of the receptor contains multiple serine/threonine residues which are phosphorylated 
by G protein receptor kinases. The phosphorylated receptor is then internalized into 
clathrin-coated pits, mediated by β-arrestins, and is thereby desensitized to further 
activation by AngII.[73, 81, 83]  
In contrast to the AT1 receptors, the AT2 receptors are highly expressed in the 
developing fetal tissue. The expression of the AT2 receptor declines after birth resulting 
in low levels of the receptor in adults. The AT2 receptors are known to antagonize the 
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effects of AT1, especially in the cardiovascular system, by inducing vasodilation, 
apoptosis and inhibition of cell growth.[73-75] 
AngII has been widely implicated in the pathophysiology of several 
cardiovascular diseases including hypertension, cardiac failure, post-myocardial 
infarction as well as diabetic nephropathy.[74] AngII is known to lead to disease 
development by acting on a variety of vascular cells such as endothelial cells, smooth 
muscle cells, fibroblasts, monocytes and macrophages, as well as cardiac myocytes.[73] 
Of particular importance is the role of AngII in vascular inflammatory diseases such as 
atherosclerosis and abdominal aortic aneurysm.[84] AngII infusion, at a dose of 1000 
ng/kg/min was found to enhance atherosclerotic lesion development in both 
apolipoprotein E-deficient as well as low-density lipoprotein receptor-deficient 
hyperlipidemic mice in 28 days.[51, 52] These lesions consisted of a significant amount 
of T lymphocytes and lipid-laden macrophages, both characteristic of atherosclerosis.[51, 
85] This enhanced development of atherosclerosis by AngII was found to be independent 
of blood pressure as arterial pressure was not increased by AngII infusion in these 
mice.[51] In addition, Weiss et al. showed that infusion of norepinephrine in 
apolipoprotein E-deficient mice, which resulted in comparable increases in blood 
pressure to that induced by AngII, produced only a modest effect on development of 
atherosclerotic lesions, as compared to the effects of AngII.[86] Thus, the above reports 
indicate that AngII plays a major role in the pathogenesis of atherosclerosis.  
Chronic infusion of AngII has been shown to result in the development of 
abdominal aortic aneurysms (AAAs) in mice. Daugherty et al. were the first to show that 
a chronic infusion of 1000 ng/kg/min AngII, delivered via subcutaneous implantation of 
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osmotic minipumps, resulted in development of suprarenal AAAs in hyperlipidemic 
mice.[51, 52] Subsequently, reports from our laboratory showed that this dose of AngII 
was also effective in producing a significant incidence of AAAs in mice of a 
nonhyperlipidemic background as well.[55, 56] The AngII infusion model has since been 
widely utilized to study the different factors which may potentially affect the 
pathophysiology of AAAs in humans.  
Formation of AAAs as well as the atherosclerotic lesions by AngII infusion has 
been reported to be markedly reduced by antagonizing the AT1 receptor with losartan. In 
contrast, utilization of an AT2 receptor antagonist was found to dramatically increase 
AAA incidence as well as the severity of atherosclerosis.[87] Additionally, genetic 
deficiency of the AT1a receptor was also found to reduce the atherosclerotic lesion area 
in these hyperlipidemic mice, while no such effect was displayed by the AT2 receptor-
deficient mice.[88] Deficiency of the AT1a receptor, particularly in the endothelial cells 
has also been recently reported to attenuate the incidence of AngII-induced ascending 
aortic aneurysms in hyperlipidemic mice.[89] Thus, the above reports suggest that the 
pathological effects of AngII in cardiovascular diseases such as atherosclerosis and 
aneurysms, is primarily mediated by the AT1a receptor. 
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1.3. PROSTAGLANDINS AND CYCLOOXYGENASES 
 
1.3.1. Prostaglandins 
Prostaglandins (PGs) are a group of biologically active lipid mediators, derived 
from arachidonic acid. The discovery of PGs dates back to the 1930s with the 
identification of a factor isolated from the prostate gland, later shown to be seminal 
vesicles, which had vasodepressor and smooth muscle contraction properties.[90, 91] 
Almost 30 years later, Samuelsson and Bergström elucidated the structures of the PGs 
and determined that they are products of the free fatty acid, arachidonic acid (AA), which 
is ubiquitously present in all cell membranes. Subsequently, PGs were isolated, 
characterized and determined to be synthesized from a variety of tissues and body 
fluids.[90-92] Following the identification of PGs, leukotrienes were discovered and were 
shown to be potent inflammatory lipid mediators associated with asthma and allergic 
reactions.[93] Prostaglandins, leukotrienes and other products derived from arachidonic 
acid are collectively known as eicosanoids. 
PGs are a group of unsaturated fatty acids containing 20 carbon atoms. The basic 
structure of PGs is prostanoic acid which includes a 5-membered cyclopentane ring. The 
different PGs are classified by letters and are grouped based on substitutions in the 
cyclopentane ring. The thromboxanes have a 6-membered ring instead of the 
cyclopentane ring. The numbered subscripts at the end of the name for each PG denote 
the number of double bonds in that compound. The major PGs are PGD2, PGE2, PGF2α 
and PGI2, which, together with thromboxane A2 (TXA2), are known as prostanoids.[91, 
94] 
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 Almost all cell types of our body, except red blood cells have the capacity to 
synthesize PGs from arachidonic acid (AA), and may be stimulated to produce PGs by 
cytokines, growth factors, immunogens, mechanical trauma, chemical irritants or other 
stimuli. AA is an unsaturated fatty acid which is present in large quantities in 
phospholipids of the cell membrane. The membrane phospholipids are acted upon by 
multiple isoforms of the enzyme phospholipase A2 (PLA2), including type IV cytosolic 
PLA2 (cPLA2), which shows selectivity for the release of AA. Various enzymes are 
known to maintain AA esterified in order to maintain its cellular levels, until mobilized 
by PLA2. Phospholipase activation is either through direct interaction of agonists with 
membrane-bound G-protein coupled receptors, or by increasing intracellular calcium 
influx. This cell-specific activation leads to translocation of cPLA2 to the nuclear 
envelope, endoplasmic reticulum or the Golgi apparatus, to ensure AA release in a 
regulated fashion.[90, 91, 94-96]  
At the ER and nuclear membrane, the released AA is acted upon by the enzyme 
prostaglandin H synthase (PGHS), commonly known as cyclooxygenase (COX). PGHS 
is present in 2 isoforms, PGHS-1 (COX-1) and PGHS-2 (COX-2). Both COX isoforms 
are known to catalyze the two reactions that result in PG synthesis. The name 
cyclooxygenase was used to describe the first of these two enzymatic activities of the 
protein. The first reaction catalyzes the addition of molecular oxygen to AA thereby 
cyclizing the molecule to the intermediate endoperoxide compound prostaglandin G2 
(PGG2). The second reaction catalyzes the conversion of PGG2 to PGH2, which 
constitutes the peroxidase activity of the enzyme. PGH2 is highly unstable and is acted 
upon by tissue-specific synthases to form the different PGs.[90, 91, 94, 96, 97] 
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Metabolism of PGH2 by the downstream synthases is the critical step which 
imparts cell specificity to the different PGs and TXA2. Differences in localization and 
cell concentration of these enzymes correlate to the production of a predominant PG 
being produced by a specific cell type, as well as being responsible for differences in PG 
production by various tissues. For example, TXA2 synthase is expressed in platelets and 
macrophages, prostacyclin synthase is expressed in endothelial cells, PGF synthase 
expression has been identified in the uterus, PGD2 synthase is widely expressed in the 
brain and mast cells, and PGE2 synthase (mPGES) is expressed by a variety of cell 
types.[90, 91, 98] 
PGs are not stored inside the cell, and are released immediately after their 
synthesis. PGs act in an autocrine or paracrine manner, i.e., they act locally at the site, or 
adjacent to the site of their synthesis. They are known to bind to specific G-protein 
coupled receptors (GPCRs) on the cell surface to produce their biological effects. 
Although the receptors are structurally similar, they are usually specific for a PG of a 
given class. There are at least 9 known PG receptors: DP1 and DP2 bind PGD2, EP1-EP4 
bind PGE2, FP binds PGF2α, IP binds PGI2 and TP binds TXA2. All of these receptors, 
except DP2, are GPCRs. IP, DP1, EP2 and EP4 are typically known as the “relaxant” 
receptors and signal through Gs-mediated increases in cyclic adenosine monophosphate 
(cAMP). In contrast, the “contractile” receptors, EP1, FP and TP signal thorough Gq-
mediated increases in intracellular calcium. The EP3 receptor is the “inhibitory” receptor 
which decreases cAMP by activating Gi. The major functions of the different PGs and 
TXA2 are listed below in Table 1.1. Since some prostanoids are labile, it is often difficult 
to measure the active compounds in the circulation under physiological conditions. Thus, 
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quantitation of the inactive metabolites in urine or other body fluids, for example, TXB2 
for TXA2, PGJ2 for PGD2, is commonly used to assess the amount of PGs produced.[90, 
91, 99, 100]  
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Table 1.1 Major functions of prostanoids in different organ systems[91] 
The major functions of the prostanoids in different organ systems are broadly classified 
below. 
  
System Mediator Effect 
Cardiovascular PGI2 Vasodilation 
TXA2 Vasoconstriction 
Hematologic PGI2 Platelet de-aggregation 
TXA2 Platelet aggregation 
Gastrointestinal PGE2 Protection of gastric mucosa 
Renal PGI2 Vasodilation 
PGE2 Salt and water excretion 
Reproductive PGF2α Contraction of uterine smooth muscle, 
parturition 
Respiratory PGI2 Vasodilation 
PGD2 Allergic asthma 
Neurologic PGE2 Fever, hyperalgesia 
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1.3.2. Cyclooxygenases 
Cyclooxygenase (COX) or prostaglandin H synthase (PGHS) is an enzyme that 
catalyzes the first 2 steps in the biosynthesis of prostaglandins (PGs) from its substrate 
arachidonic acid (AA). COX activity has been studied since the 1980s, originally using 
preparations from sheep seminal vesicles.[101] In 1990, Fu et al. were the first to report 
the de novo synthesis of a new COX protein synthesized by human monocytes when 
stimulated by cytokines and other inflammatory mediators.[102] The novel COX protein 
was shown to be a distinct isoform of the previously identified COX enzyme, although 
there was sequence homology between the two isoforms. Thus, the 2 isoforms of COX 
were named COX-1 and COX-2, and are encoded by different genes located on different 
chromosomes.[91, 103]  
Both COX-1 and COX-2 have similar tertiary structures and are known to carry 
out the same catalytic reaction.[104] However, while COX-1 is considered to be 
responsible for basal, constitutive PG synthesis, COX-2 is known to synthesize primarily 
the pro-inflammatory PGs when induced by certain stimuli. Thus, COX-1 has been 
described to maintain the physiological “housekeeping” functions of the body, whereas 
COX-2 regulates the inflammatory response under “induced” conditions. This correlates 
to expression of COX-1 in a variety of organs in the body which usually show low to 
undetectable levels of COX-2 under normal conditions. In particular, a high level of 
COX-1 is found to be constitutively expressed in vascular endothelial cells, platelets, 
kidney and the stomach, and is thereby responsible for synthesizing the prostanoids 
which would maintain the homeostatic functions of these tissues and organs. In contrast, 
COX-2 is primarily an inducible enzyme and is traditionally thought to play an important 
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role in the production of prostanoids that contribute to pathological conditions. COX-2 is 
localized in the nuclear envelope, and a variety of pro-inflammatory stimuli are known to 
increase expression of COX-2 in various cells and tissues. These stimuli include 
cytokines such as interleukin-1 (IL-1), IL-2, tumor necrosis factor-α (TNF-α), INF-, 
lipopolysaccharide (LPS), TPA, hormones such as FSH and LH, and several growth 
factors such as EGF, PDFG and FGF, among others.[91, 104-106]  
Both isoforms of COX have a molecular weight of 71 kDa, and are approximately 
600 amino acids in length. COX-1 and COX-2 are known to share 63% sequence 
homology.[106] X-ray crystallographic studies have revealed much about the 3-D 
structures of COX-1 and COX-2. Thus 3 distinct domains are known to comprise the 
structure of the COX proteins: an N-terminal epidermal growth factor domain, a 
membrane binding motif, and a C-terminal catalytic domain that consists of the COX and 
peroxidase active sites.[107, 108]  
 
1.3.3. Inhibition of COX activity 
In 1971, Vane was the first to demonstrate that the anti-inflammatory activity of 
aspirin, which had been used as an anti-inflammatory, anti-pyretic and analgesic since 
1889, and other non-steroidal anti-inflammatory drugs (NSAIDs), was due to the 
inhibition of COX, and subsequent PG synthesis.[109] NSAIDs are known to inhibit both 
COX-1 and COX-2 non-specifically in a variety of ways. While aspirin covalently 
impairs the AA binding site to COX, ibuprofen is a reversible competitive inhibitor of 
COX that competes with AA for the COX active site, whereas indomethacin causes a 
slow irreversible inhibition of COX.[110, 111]  
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Chronic use of the traditional NSAIDs, which inhibit both COX-1 and COX-2, is 
associated with severe side effects which may include gastrointestinal ulceration and 
bleeding, renal damage and platelet dysfunction. Since COX-1 is a constitutive enzyme 
maintaining “housekeeping” functions in these tissues, the side-effects of NSAIDs were 
considered to be due to inhibition of COX-1. Also, since COX-1 is not upregulated 
during inflammatory conditions, when COX-2 plays a major role, the beneficial effects of 
the NSAIDs during pain and inflammation were attributed primarily to inhibition of 
COX-2. This concept provided the rationale for the development of a new series of 
compounds which would selectively inhibit COX-2, and thereby maintain the therapeutic 
efficacy of the traditional NSAIDs, without adverse effects resulting from the inhibition 
of COX-1.[106, 112] 
Although the structures of COX-1 and COX-2 were found to be similar, X-ray 
crystallography revealed that there is a single amino acid difference between the 2 
enzymes, which could offer selectivity during drug development for isoform-selective 
inhibitors. At position 523, COX-1 has the amino acid isoleucine, whereas, COX-2 
contained valine, which is smaller than isoleucine by a single methyl group. Thus, the 
smaller valine in COX-2 is thought to create a side-pocket and thereby provide additional 
access to the drugs. On the other hand, the bulkier isoleucine in COX-1 blocks this access 
to the side-pocket. Thus, bulkier molecules, such as celecoxib and rofecoxib, which could 
bind to the COX-2 side-pocket, but could not access the active site of COX-1, were 
subsequently developed to attain COX-2-selective inhibition.[113, 114]  
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1.3.4. Celecoxib 
Celecoxib (Celebrex®) was the first of the “coxibs”, the group of COX-2-selective 
inhibitors that were introduced more than a decade ago. Celecoxib is approved worldwide 
primarily for the treatment of inflammatory conditions such as arthritis, spondylitis and 
acute or chronic musculoskeletal pain. Celecoxib has similar efficacy as the traditional 
NSAIDs in reducing arthritis, but provides improved GI tolerability due to selective 
inhibition of COX-2. The molecule is a 1, 5-diaryl pyrazole-based compound that is 30 
times more potent at inhibiting COX-2 than COX-1. The selectivity of celecoxib for 
COX-2 is approximately 10 to 15 times less than that of other coxibs.[115] The analgesic 
and anti-inflammatory actions of celecoxib, at the therapeutic dose of 200-400 mg/day, 
are mediated through COX-2 inhibition, and not COX-1, as assessed by TXA2 formation. 
Celecoxib has been reported to have no significant effect on platelet function in healthy 
volunteers, and effects on renal function are comparable to other NSAIDs.[114-117] 
COX-2-selective inhibitors have been shown to produce less gastrointestinal 
toxicity, although their chronic use is associated with an increased risk of serious adverse 
cardiovascular events.[118] Although the COX-2-selective inhibitor rofecoxib was 
withdrawn from the market due to an increase in these adverse cardiovascular effects 
following chronic administration, the level of risk associated with celecoxib use is 
reported to be significantly lower than that observed for rofecoxib.[119] In addition, a 
number of reports have determined the level of cardiovascular risk associated with 
celecoxib use to be comparable to, or lower than nonselective NSAIDs.[120, 121] 
However, chronic administration of celecoxib doses higher than those approved for 
treating osteoarthritis was shown to increase adverse cardiovascular events when 
 
25 
 
compared to placebo, and the risk was greater for patients with preexisting cardiovascular 
disease.[122] A prospective trial designed to compare the cardiovascular safety of 
celecoxib with two other commonly used NSAIDs in patients with preexisting 
cardiovascular disease is currently in progress.[123] The therapeutic value of celecoxib as 
a potential treatment for AAAs may ultimately depend on the level of adverse 
cardiovascular effects that result from this medication.  
 
1.3.5. COX-2 and abdominal aortic aneurysms 
Human abdominal aortic aneurysms (AAAs) are characterized by a systemic 
increase in inflammatory mediators, as well as localized inflammation in the vascular 
wall.[4, 124] The prostanoids are believed to play an important role in regulating these 
inflammatory processes.[4, 125] While both COX-2 and the resultant PGE2 have been 
found to be induced in the aneurysmal tissue, COX-1 was not significantly altered.[4] 
Using the AngII-induced model of AAAs, we have reported that the incidence and 
severity of AAAs following AngII infusion are significantly reduced in hyperlipidemic 
Apoe-/- mice, as well as non-hyperlipidemic COX-2 wild type mice, pre-treated with 
COX-2 selective inhibitor, celecoxib[55]. Genetic deficiency of COX-2 is also found to 
significantly reduce AAA formation in the mice. While AngII was found to induce COX-
2 mRNA in the aorta, significant COX-2 protein expression was also detected in the 
medial smooth muscle cells (SMCs) of the abdominal aorta.[56] These findings 
demonstrate that COX-2 plays an important role in the development of AAAs. 
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Figure 1.1 Illustration of the cyclooxygenase pathway 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
1.4. SMOOTH MUSCLE CELL PHENOTYPE 
 
1.4.1. The smooth muscle cell 
The normal blood vessel is composed of three basic layers: the intima, the media 
and the adventitia. The intima is composed of a single continuous layer of endothelial 
cells and is separated from the medial layer by the internal elastic lamina. The media is 
composed exclusively of smooth muscle cells (SMCs), within concentric layers of elastic 
lamina. The external elastic lamina separates the media from the adventitia which 
comprises of connective tissue, fibroblasts, capillaries and fat cells.[126] 
The major function of the mature smooth muscle cell (SMC) is to contract and 
thereby regulate blood vessel tone and diameter, blood pressure and distribution of blood 
flow. For maintaining these contractile functions, SMCs are known to express a variety 
of contractile proteins, receptors and ion channels, and signal transduction molecules, 
many of which are unique from those expressed by other cell types.[127, 128] 
 
1.4.2. Phenotypic plasticity of SMCs 
Arterial SMCs are known to originate from the mesoderm. During development, 
mesenchymal cells in the embryo accumulate and begin a gradual differentiation into 
SMCs which initially develop an appearance similar to fibroblasts. At this stage, the 
cytoplasm of these SMCs contains large amounts of rough endoplasmic reticulum (RER), 
a prominent Golgi complex, and free ribosomes, with only a few myofilaments, and their 
main functions are to proliferate and to produce extracellular matrix components which 
include collagen and elastin. These cells also typically express β-actin as the major actin 
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isoform, and vimentin as the intermediate filament protein. This phenotype of SMCs 
which is the state most associated with formation of the vessel wall is known as the 
“synthetic” phenotype.[129] 
As the blood vessels mature, the SMCs are known to undergo a change in their 
phenotype. This is evident by a progressively decreasing size of the synthetic organelles, 
with the myofilaments occupying the majority of the cytoplasm. The cells tend to lose 
their synthetic and proliferative capabilities, and instead attain the ability to contract. 
Moreover, there is a significant decrease in the content of β-actin and these SMCs instead 
begin expressing α-actin as the major actin isoform, along with a host of other proteins of 
the contractile apparatus, including desmin, myosin, tropomyosin, h-caldesmon and 
others. Thus, the SMCs comprising the fully developed media are known to attain a 
phenotype referred to as the “contractile” or the “differentiated” phenotype.[129] 
Although the developmental changes involving the differentiation of SMCs are 
very similar to those of cardiac or skeletal muscle cells, these cells typically undergo a 
terminal and irreversible differentiation.[130, 131] In contrast, vascular SMCs are 
thought to retain considerable plasticity and can undergo extensive, as well as, reversible 
changes in their phenotype in response to physiological and pathological stimuli. Thus, 
although its major function is contraction, the SMC, by virtue of its phenotypic plasticity, 
can execute a variety of other functions at different developmental stages, during vascular 
repair, or in case of certain vascular diseases.[127, 132] This characteristic of the SMC is 
probably most evident in response to vascular injury, when fully differentiated SMCs 
have the capacity to undergo “de-differentiation” and revert back to a synthetic 
phenotype. At this stage, these de-differentiated SMCs have drastically increased rates of 
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proliferation and migration, together with synthesis of the extracellular matrix 
components which are essential for vascular repair. Upon resolution of the injury, the 
factors which initially stimulated the repair process return to normal, thereby prompting 
the SMCs to reassume their contractile phenotype.[127, 128] 
A major drawback of the high degree of plasticity displayed by SMCs is their 
ability to respond to abnormal environmental signals, which can lead to adverse 
phenotypic switching, aiding in the development of major vascular diseases. Vascular 
SMC proliferation and de-differentiation have been found to contribute to a variety of 
pathological processes including atherosclerosis, hypertension, and coronary 
restenosis.[132-134] 
 
1.4.3. Markers of SMC phenotypes 
The diversity of SMC phenotypes are studied based on changes in morphology, 
expression levels of SMC marker genes, and the proliferative and migration potential of 
the SMCs. However, it is important to note that the contractile and synthetic SMCs 
represent two opposing ends of a broad phenotypic spectrum, and SMCs may exist as 
intermediate phenotypes. Morphology of cultured SMCs is considered to be an important 
parameter to describe the different SMC phenotypes. While contractile SMCs are 
elongated and spindle-shaped cells, the synthetic SMCs are less elongated and are known 
to display an epithelioid or rhomboid appearance. Several studies have also shown that 
the synthetic or de-differentiated cells have higher rates of proliferation and migration 
compared to the differentiated cells.[135] However, in addition to these qualitative 
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parameters, the quantitative analysis of levels of marker proteins has been suggested to be 
the ideal method for characterization of the different SMC phenotypes.[136] 
 
1.4.3.1. Markers of contractile SMC phenotype 
A variety of SMC-selective or specific genes have been identified which are 
utilized as markers to classify the SMC phenotypes. A majority of these are contractile 
proteins, the levels of which represent the relative state of differentiation of SMCs. These 
proteins include smooth muscle (SM) α-actin, SM myosin heavy chain (MHC), calponin, 
SM22α, desmin and smoothelin among others.[128] Since the expression of these 
proteins are regulated at the gene levels, such as transcription and splicing, they are 
suitable for use as molecular markers for SMC phenotypes.[137]  
The actin isoforms are usually classified into two major groups: muscle and non-
muscle actin, and are indicated by α, β or  based on their isoelectric points. Of these, 
SM α-actin, a major protein for SMC contraction, is highly selective for and is the most 
abundant protein of adult SMCs in the contractile phenotype, making up approximately 
40% of the total protein content.[128, 138] SM α-actin is the first known protein 
expressed during differentiation of the SMCs in the course of development, undergoing 
significant increases in expression even later during vascular development.[127, 139] In 
contrast, aortic SMCs in proliferating cultures undergoing phenotypic modulation have 
been shown to have a decreased mRNA as well as protein content of α-actin, whereas 
non-muscle β-actin expression is increased.[129, 140] Thus, α-actin is one of the most 
widely utilized markers to define the contractile SMC phenotype. 
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Another marker of differentiated SMC phenotype that has been used extensively 
is the 22kDa protein, SM22α. Of the three isoforms of SM22, α isoform is the most 
dominant, and is expressed abundantly in SMCs of the adult. It is one of the earliest 
markers of differentiated SMC, and is expressed in a pattern very similar to SM α-actin. 
Although the functions of SM22α remain largely unclear, some studies have suggested its 
role in the regulation of SMC contraction.[127, 128, 136, 137, 141] 
Desmin is the principal intermediate filament protein expressed in differentiated 
SMCs of the adult. Although detectable levels of desmin are not found in large 
mammalian arteries, rodent aortas have been reported to express low levels of 
desmin.[142] Thus, while vimentin is the intermediate filament protein typically 
expressed in the synthetic SMCs, desmin has been utilized as a useful marker to assess 
the relative state of differentiation of vascular SMCs existing in the contractile 
phenotype.[127, 143] 
Calponin is a calcium regulatory protein expressed selectively in differentiated 
SMCs. It is known to interact with F-actin and tropomyosin in a calcium independent 
manner, but with calmodulin in a calcium dependent manner, and thereby regulates 
contraction of SMCs.[127] Calponin can exist in two isoforms: acidic and basic 
calponin.[137] While acidic calponin is expressed in both smooth muscle and non-muscle 
tissues, basic calponin is exclusively expressed in contractile smooth muscles, and has 
been shown to be down-regulated in de-differentiated SMCs.[144] Based on these 
reports, calponin is considered an important marker to identify differentiated SMCs. 
Myosin is a major protein of the contractile apparatus of SMCs multiple isoforms 
of which have been identified. Of these, two variants, SM1 and SM2 are expressed 
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specifically in mature contractile SMCs, towards the later part of the developmental 
stage. Vascular SMCs are also known to express two non-muscle isoforms, NMHC-A 
and NMHC-B. Of these, NMHC-B is similar to SMemb which is expressed in synthetic 
SMCs of the embryonic aorta and in neointimal lesions.[145] Thus, myosin heavy chains, 
with their high degree of specificity for expression in contractile SMCs, are suggested to 
be one of the most discriminating markers of differentiated SMCs identified to date.[127, 
136, 137] 
Smoothelin has been suggested to be selectively expressed in differentiated SMCs 
in two isoforms: type A and type B. Of these, type B isoform of smoothelin is thought to 
be expressed only in contractile vascular SMCs.[127] The expression of smoothelin has 
also been shown to be down-regulated in cultured SMCs modulating towards a de-
differentiated phenotype.[146] Thus, being even more sensitive than the myosin heavy 
chains, smoothelin has been suggested to be a well-characterized marker of contractile 
SMC phenotype.[136] 
 
1.4.3.2. Markers of synthetic SMC phenotype 
As SMCs alter their phenotype from a contractile to a synthetic state, the 
expression of the above mentioned contractile markers which are up-regulated during the 
differentiated state, are in turn decreased.[127, 137, 147] However, the extent of 
reduction in expression of these markers varies. Since the expression of markers which 
are found to be increased in the synthetic phenotype is rare, the decrease in expression of 
the contractile markers is generally assumed to be a characteristic of the synthetic 
phenotype of SMCs.[127, 136]  
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Alteration of SMCs to a de-differentiated phenotype is also associated with 
increased rates of proliferation and migration of the cells, together with synthesis of 
components of the extracellular matrix (ECM) such as collagen, elastin and hyaluronic 
acid.[127, 129, 136] Studies with primary culture of arterial SMCs show that rapid 
proliferation of phenotypically modulated SMCs are associated with high rates of 
collagen and elastin synthesis. Type I is the main type of collagen reported to be 
produced in these studies, with smaller amounts of type III and type V also being 
detected.[148] Similarly, Ang et al. have also reported an increase in expression of nearly 
25-30 times more collagen by phenotypically altered SMCs, compared to levels produced 
by cells in the contractile state.[149]  
Apart from collagen, alteration of the SMC phenotype is also associated with 
increased synthesis of glycosaminoglycans which are long unbranched 
polysaccharides.[150] Hyaluronan or hyaluronic acid (HA) is an unsulphated 
glycosaminoglycan and is a principal component of the extracellular matrix. HA is a 
linear high molecular weight polymer consisting of repeating disaccharide units of (β1 
3)D-glucuronate-(β1     4)N-acetyl-D-glucosamine. HA is synthesized by three 
glycosyltransferases on the plasma membrane known as hyaluronic acid synthases 
(HAS1, HAS2 and HAS3). HAS2 is the major HAS isoform found to be expressed in 
vascular SMCs, which express very low levels of HAS1 and HAS3.[151] HAS2 protein 
is localized at the cell surface and extrudes HA directly to the extracellular space 
following synthesis. Volume expansion of the extracellular space is also observed due to 
binding of HA with salt and water.[152, 153]  
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HA has been implicated in several vascular diseases including atherosclerosis, 
restenosis and other models of vascular injury which involve an increase in expression of 
HA, HA synthases, or the HA receptor CD44. These vascular diseases have also been 
shown to be associated with changes of the SMC phenotype from that of a contractile cell 
to one which migrates to the intimal space, proliferates rapidly to produce the neointima, 
and synthesizes abundant extracellular matrix, and HA has been suggested to be a 
principal component of this extracellular matrix.[154-157] A study utilizing human 
vascular SMCs has reported that in response to platelet-derived growth factor (PDGF), a 
potent mitogen, HA secretion is significantly increased in the proliferating cells.[158] 
This was followed by studies by Evanko et al. who showed that PDGF stimulates the 
formation of hyaluronan and versican-rich pericellular matrices around arterial SMCs. 
They also reported an increase in expression of hyaluronan synthase 2 as well as HA in 
these cells, suggesting a link between ECM expansion and alterations in SMC 
phenotype.[151] Thus, the above reports suggest that HA is one of the major ECM 
components synthesized by SMCs of de-differentiated phenotype, and thus, can be used 
as an effective marker for identifying the synthetic SMCs. In addition, since HAS2 is the 
major isoform among HA synthases expressed in SMCs, for our current studies, we have 
utilized HAS2 as a marker of SMC de-differentiation in the aorta. 
 
1.5. PURPOSE OF STUDY 
 AAA is a chronic inflammatory disease with both COX-2 and PGE2 being 
induced in human aneurysmal tissues. Using a mouse model of the disease, previous 
studies in our laboratory were the first to report the importance of COX-2 in AngII-
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induced AAA formation in mice by utilizing mice genetically deficient in COX-2 or pre-
treating them with a COX-2-selective inhibitor celecoxib. With no pharmacological 
treatments currently available for AAAs, the purpose of the current studies was to further 
illustrate the role of COX-2 inhibition during AngII-induced AAA progression in mice, 
as well as elucidate the mechanisms contributing to disease formation in the mouse 
abdominal aorta. 
 
1.6. SPECIFIC AIMS 
1.6.1. Specific aim 1 
The 1st aim of the current studies was to determine the role of COX-2 inhibition 
with celecoxib in attenuating progression of AngII-induced AAAs in mice, when 
treatment is begun after initiation of the disease. We hypothesized that beginning 
treatment with celecoxib after initiation of aneurysmal pathology, will reduce the 
incidence and severity of AngII-induced AAAs in mice at different stages of disease 
progression. 
1.6.2. Specific aim 2 
The 2nd aim of the current studies was to elucidate the mechanisms contributing to 
the increased susceptibility of the abdominal region of the aorta towards AngII-induced 
aneurysm formation in mice. We hypothesized that increased COX-2 expression in the 
abdominal region, as compared to the other regions of the aorta, causes the abdominal 
region of the aorta to become more susceptible towards AngII-induced aneurysm 
development in mice.  
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1.6.3. Specific aim 3 
The 3rd aim of the current studies was to determine the mechanisms by which 
COX-2 inhibition regulates the development of AngII-induced AAAs in mice. We 
hypothesized that COX-2 inhibition with celecoxib maintains smooth muscle cells of the 
aorta in a more differentiated phenotype during attenuation of AngII-induced AAA 
progression in mice.  
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CHAPTER 2 
METHODS 
 
The experiments described in the later chapters of this dissertation are based on 
utilization of common techniques. Thus, to avoid repetition, the general experimental 
methods used in all the subsequent chapters have been outlined below. 
 
2.1. Animals 
Fourteen week old male nonhyperlipidemic mice of a mixed C57BL/6J X 129/Ola 
genetic background (Taconic Farms Inc.) were used for the current studies. The mice 
were housed under barrier conditions at the University of Kentucky, College of Pharmacy 
animal facility, with food and water provided ad libitum. All studies were performed with 
the approval of the University of Kentucky Institutional Animal Care and Use Committee 
and conform with the Guide for the Care and Use of Laboratory Animals published by 
the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). 
 
2.2. Angiotensin II infusion  
For subcutaneous osmotic pump implantation, mice were anesthetized with 
isoflurane at a concentration of 2% in oxygen that was delivered using a precision 
vaporizer and an induction box. Saline or Angiotensin II (AngII, Sigma, St. Louis, MO) 
were then filled into Alzet osmotic minipumps (model 2004; ALZA Scientific Products, 
Mountain View, CA) and delivered subcutaneously at a rate of 1000 ng/kg/min for 3, 7, 
14, 21 or 28 days. Pumps were placed into the subcutaneous space of anesthetized mice 
through a small incision in the back of the neck that was closed with wound clips. The 
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wound clips were removed after 2 weeks and all incision sites healed rapidly without the 
need for additional medication.[51]  
 
2.3. Study designs 
2.3.1. COX-2 inhibitor studies 
This section describes the COX-2 inhibitor studies in Chapters 3 and 6. Fourteen 
week old male nonhyperlipidemic mice were infused with 1000 ng/kg/min AngII, as 
described above in section 2.2. Five days after beginning the AngII infusion, the mice 
were divided into two groups. One group received a control diet (normal chow diet; 
Research Diets Inc., New Brunswick, NJ), while the other group received a diet 
containing COX-2-selective inhibitor celecoxib (normal chow diet re-pelleted with 1000 
ppm celecoxib, LKT Laboratories, St Paul, MN). The mice were subsequently sacrificed 
and abdominal aortas were collected after 14, 21 and 28 days of AngII infusion. Tissues 
from these experiments were used for analysis of vascular pathology (as described in 
Chapter 3), as well as gene expression, and protein expression of smooth muscle cell 
phenotypic markers (as described in Chapter 6) by real-time PCR and histochemical 
techniques, respectively, which are described below in sections 2.8 and 2.9. 
 
2.3.2. Studies with different aortic segments 
This section describes the studies with the different aortic segments in Chapter 4. 
Fourteen week old male nonhyperlipidemic mice were infused with saline or 1000 
ng/kg/min AngII, as described above in section 2.2. The mice were subsequently 
sacrificed after 3, 7, 14, 21 and 28 days of the infusion. The arch, thoracic and abdominal 
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regions of the aorta were collected and analyzed for COX-2 and AT1a receptor gene 
expression by real-time PCR, and protein expression by immunohistochemistry, as 
described below in sections 2.8 and 2.9 respectively. 
 
2.3.3. Cell proliferation studies 
This section describes the smooth muscle cell proliferation studies in Chapter 5. 
Fourteen week old male nonhyperlipidemic mice were infused with saline, or 1000 
ng/kg/min AngII by osmotic mini-pumps, as described above in section 2.2. Following 
the implantation of the pumps, the mice were intraperitoneally injected with 
bromodeoxyuridine (BrdU) (Invitrogen, CA) at a dose of 100 mg/kg, dissolved in saline, 
every 24 hours. The mice were subsequently sacrificed after 7 or 14 days of AngII 
infusion. The abdominal segments of the aorta and skin samples (for positive control) 
were collected and analyzed for cell proliferation by BrdU immunohistochemistry, as 
described below in section 2.9.1. 
 
2.3.4. COX-2 knockout studies 
This section describes the COX-2 knockout studies in Chapter 6. Fourteen week 
old non-hyperlipidemic COX-2 wild-type (WT) or COX-2 knockout (KO) mice were 
infused with AngII at a dose of 1000 ng/kg/min, as described above in section 2.2. The 
mice were subsequently sacrificed after 7 days of AngII infusion. The abdominal aortas 
were then collected and analyzed for gene expression of markers of the SMC phenotypes 
by real-time PCR, which is described below in section 2.8. 
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2.4. Tissue collection  
For performing euthanasia, mice were first anesthetized by intra-peritoneal 
injection of ketamine (100 mg/kg) (Fort Dodge Animal Health, Iowa) and xylazine (10 
mg/kg) (Ben Venue Laboratories, Bedford, OH) until unresponsive to pain, followed by 
thoracotomy and exsanguination under anesthesia. The aortas were excised and divided 
into 3 segments, with the arch section beginning from adjacent to the heart to the left 
subclavian artery, the thoracic beginning from the left subclavian artery to the last set of 
intercostals, and the abdominal section beginning from the end of the intercostals to the 
bifurcation of the aorta into the common iliac arteries.  
For RNA experiments, the aortas were excised and divided into arch, thoracic and 
abdominal segments, and stored in RNALater (Sigma, St Louis, MO) at -20ºC to 
maximize RNA stability.  
For histochemical experiments, the mice were perfused with saline, followed by 
1:10 neutral buffered formalin (Fisher, Kalamazoo, MI) solution. The aortas were excised 
and divided into segments as described above. The tissues were then fixed in 1:10 neutral 
buffered formalin overnight, followed by 70% ethanol (Fisher, Kalamazoo, MI), and 
subsequently stored in 70% ethanol at 4ºC. 
 
2.5. Vascular pathology 
AAAs were quantified as percentage incidence of aneurysms, with a maximal 
external diameter of ≥ 1.5 mm of the abdominal section of the aorta, considered as an 
incidence of aneurysm. The mice which had a ruptured aorta and subsequent death due to 
hemorrhage before the completion of the study were not included in calculating the AAA 
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incidence. Ruptured aneurysms were quantified as percentage incidence of rupture of the 
aorta between day 6 and day 17 of AngII infusion. AAA severity was determined by 
classifying the AAAs as Type 1, where the external diameter of the abdominal aorta was 
between 1.5 – 1.9 mm, and those as Type 2, where the external diameter was ≥ 2 mm.  
 
2.6. RNA isolation 
Total RNA was extracted from the tissues collected using RNEasy Mini kits 
(Qiagen, Valencia, CA). The RNEasy method utilizes a combination of binding 
properties of a silica-based membrane with the speed of microspin technology. The aorta 
tissue samples were first lysed in a glass micro-mortar and pestle apparatus, and then 
homogenized using a highly denaturing guanidine-thiocyanate containing buffer, which 
also inactivates RNAses, to ensure purification of intact RNA. The lysate was then 
diluted with an ethanol solution, which allowed the RNA to bind the silica membrane in 
the RNEasy Mini spin column. The solution was passed through the spin column, which 
effectively binds the RNA. The spin column was washed 3 times using wash buffer to 
allow removal of contaminating materials. RNA was then eluted using RNAse-free 
water. 
 
2.7. cDNA preparation 
Reverse transcription was used to synthesize complimentary DNA (cDNA) from 
the total RNA. RNA was reverse transcribed using the following components: random 
hexamers (used at a 1:60 dilution), 5X reverse transcription buffer, deoxynucleotide 
triphosphate mix (dNTPs), RNAse inhibitor, Superscript II reverse transcriptase and 
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diethyl pyrocarbonate (DEPC) water. The reverse transcription was carried out using a 
thermal cycler (Eppendorf) with the following conditions: RNA + hexamers + dNTPs at 
65°C for 5 min followed by placing the mixture on ice for 5 min. This was followed by 
addition of the remaining components with continued incubation in the thermal cycler 
with the following conditions: 25°C for 10 minutes, 42°C for 50 minutes and 70°C for 15 
minutes to terminate the reaction. This cDNA was stored at -20ºC until utilized for gene 
expression analysis. 
 
2.8. Quantification of mRNA expression 
Gene expression quantitation was performed in a two-step quantitative real time 
PCR (qRT-PCR) (ABI Prism 7000 system) in which the PCR step is coupled with 
fluorogenic 5' nuclease chemistry (Taqman chemistry). To account for variability in the 
starting material between samples, mRNA encoding the housekeeping gene hypoxanthine 
phosphoribosyl transferase (HPRT) was quantitated for an internal normalizing control. 
Primer/probe assays (COX-2, AT1a, α-actin, desmin, SM22α, Cnn1, Myh11, Smtn, Has2 
and HPRT) were purchased from Applied Biosystems (Assays-on-Demand). A relative 
standard curve using RNA from lung tissue was run within the same reaction. The 
quantity of mRNA for the unknown gene was extrapolated from the standard curve, 
followed by normalization with the HPRT levels.  
 
2.9. Histology 
The stored tissues were processed in an automated tissue processor which exposes 
the tissues through a series of ethanols and xylenes. The tissues were then embedded in 
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paraffin and sectioned on a microtome at a thickness of 6µm. The sections were 
deparaffinized, and then subjected to histological analysis. At least 10 sections from each 
animal, with a minimum of 3 animals per group, were analyzed for each experiment. 
 
2.9.1. BrdU immunohistochemistry 
The tissue sections were deparaffinized and hydrated by treatment with xylene 
(Fisher) and ethanols (Fisher) respectively. In order to expose the antigen to the antibody, 
the sections were treated 2N hydrochloric acid (Sigma, St Louis, MO) at 37ºC for 30 
minutes. The sections were then treated with boric-acid-borate buffer for 1 minute and 
with 0.01% trypsin (Invitrogen, CA) and incubated at 37ºC for 10 minutes. The sections 
were subsequently blocked with 1% bovine serum albumin (BSA) in phosphate buffered 
saline (PBS) for 30 minutes at room temperature and incubated with a biotinylated 
primary antibody against BrdU (Invitrogen, CA), at a concentration of 1:400 overnight at 
4ºC. The sections were then processed as recommended in the Vectastain ABC Elite Kit 
(Vector Labs) for detection with 3, 3-diaminobenzidine (DAB) (Vector Labs), which 
produced a brown staining, followed by hematoxylin (Sigma, St Louis, MO) for 
counterstaining. 
 
2.9.2. COX-2 and α-actin immunohistochemistry 
Deparaffinized and hydrated tissue sections were heated with antigen retrieval 
buffer, containing citrate, at 96ºC, in a microwave oven, in order to expose the antigen to 
the antibody. The sections were cooled for 30 minutes at room temperature, and 
subsequently blocked with 1% BSA in PBS for 30 minutes at room temperature. Primary 
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antibodies against COX-2 (Vector Labs) and α-actin (Dakocytomation, CA), at 
concentrations of 1:200, were used for immunohistochemical detection of COX-2 and α-
actin, respectively, with subsequent use of an anti-rabbit secondary antibody. The 
sections were incubated with the primary antibody overnight at 4ºC, and then with the 
secondary antibody for 30 mins at room temperature. The sections were then processed as 
recommended in the Vectastain ABC Elite Kit (Vector Labs) for detection with 3, 3-
diaminobenzidine (DAB) (Vector Labs), which produced a brown staining, followed by 
hematoxylin (Sigma, St Louis, MO) for counterstaining. 
 
2.9.3. Histochemical analysis of hyaluronic acid 
Deparaffinized tissue sections were incubated with a solution containing 1:200 
hyaluronic acid binding protein (HABP), overnight at 4ºC. Since the HABP is 
biotinylated, the sections were subsequently processed as recommended in the Vectastain 
ABC Elite Kit for detection with DAB, which produced a brown staining, followed by 
hematoxylin for counterstaining. 
 
2.9.4. Collagen staining 
Collagen content in the aortic tissues was evaluated by staining with Masson’s 
trichrome stain (Newcomer Supply, WI). This stain is typically used to differentiate 
between collagen and smooth muscle cells, by utilizing 3 dyes. Masson’s trichrome stain 
employs a very basic rule of staining: the less porous tissues are colored by the smallest 
dye molecule. The sections were stained first with an acid dye, Biebrich Scarlet, which 
binds with the acidophilic tissue components, including cytoplasm, smooth muscle and 
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collagen, and stains these tissues red. The sections were then treated with 
phosphotungstic and phosphomolybdic acids. Because the smooth muscle is much less 
permeable than collagen, the phospho acids cause the Biebrich scarlet to diffuse out of 
the collagen, but not out of the muscle. Finally a large dye, such as aniline blue was used 
to stain the collagen. Thus, the smooth muscle cell layer stained red, while the collagen 
stained blue.[159]  
 
2.10. Statistical analysis 
The mean and SEM were calculated for each parameter with an individual aorta 
from a single mouse considered as an n of 1. Significant differences in AAA incidence 
among different groups were determined using χ2 analysis. Statistical significance of 
quantitative PCR data was determined using the unpaired t-test. Differences were 
considered statistically significant at p < 0.05. Data were analyzed using the GraphPad 
Prism software. 
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CHAPTER 3 
 
COX-2 INHIBITION IMPROVES SURVIVAL AND LIMITS EXPANSION OF 
ABDOMINAL AORTIC ANEURYSMS IN MICE 
 
Introduction 
 
Abdominal aortic aneurysms (AAAs) are a major health concern in the ageing 
population mostly affecting men over the age of 55 years.[2] AAAs are a chronic 
condition that begin as minor vessel dilation that progress over years to produce a 
weakened aorta with increased susceptibility for rupture, which has greater than a 90% 
incidence of mortality.[4, 5] Surgery is the only treatment option for AAAs and is 
reserved for the most severe cases with a high probability of rupture because of 
significant risk associated with surgical repair.[6, 40, 160] Although AAAs are readily 
detected by non-invasive imaging methods at various stages of progression, no 
pharmacological treatments are currently available to slow progression of the disease.[6, 
161]  
Human AAAs are characterized by inflammation of the involved aorta and 
increased production of prostaglandin (PG) mediators of inflammation.[38] The synthesis 
of PGs requires the activity of a prostaglandin G/H synthase, also known as 
cyclooxygenase (COX), of which exist the constitutively expressed isoform COX-1 and 
the inducible isoform COX-2.[162] Human aneurysmal tissue expresses predominantly 
the COX-2 isoform, and COX-2-selective inhibitors have been proposed as a potential 
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pharmacological treatment for AAAs.[4, 38] 
Using a mouse model of AAAs induced by chronic AngII infusion, we previously 
determined that pre-treatment with the COX-2-selective inhibitor celecoxib prior to 
disease initiation reduces AAA formation, whereas a COX-1-selective inhibitor is not 
effective.[55] Furthermore, we have shown that AngII-induced AAA formation is 
significantly reduced in mice deficient in COX-2.[56] The genetic deficiency of 
microsomal prostaglandin E synthase-1, which contributes to PGE2 synthesis downstream 
COX-2, also reduces AngII-induced AAA formation.[163] These findings demonstrate 
that the inactivation of COX-2 or PGE2 synthesis prior to initiating AAA formation 
reduces subsequent development of the disease.  
In addition to COX-2, the AngII infusion model in mice has been utilized to 
explore a variety of mechanisms that contribute to AAAs. Previous reports have 
suggested the potential benefit of pre-treatments administered before AngII infusion in 
reducing AAA formation in mice.[66, 164] An additional study examining leukotriene 
receptor antagonism showed the utility of treatment when first administered at the 
beginning of the AngII infusion. However, treatment with the leukotriene receptor 
antagonist was not effective when it was administered after beginning the AngII 
infusion.[165] Therefore, medications that are shown to be effective in reducing AngII-
induced AAAs following pre-treatment with the agent, may not produce similar 
effectiveness in reducing AAA progression when treatment is started after initiation of 
the disease. This suggests the importance of identifying an effective pharmacological 
treatment that can reduce progression of the disease after it has been diagnosed.  
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We therefore hypothesized that COX-2 inhibition can effectively attenuate AngII-
induced AAA progression in mice, when treatment is begun after initiation of the disease. 
In the current study, we utilized mice infused with AngII, and treated with a control diet 
or diet containing COX-2-selective inhibitor celecoxib, to investigate the role of COX-2 
in AngII-induced AAA development.  
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Results 
 
3.1. COX-2 inhibitor treatment begun after initiation of the disease effectively 
reduces AAA incidence  
The infusion of AngII produces rapid development of aneurysmal pathology in 
the abdominal aorta with the earliest effects occurring during the first 3 days of the 
infusion.[54, 56] To examine the effect of COX-2 inhibition when started after the 
initiation of AAA formation, celecoxib treatment was begun 5 days after beginning the 
AngII infusion. The mice were then sacrificed at different time-points during the AngII 
infusion for analysis of the abdominal aorta during AAA progression. The analysis of 
AAA incidence after 14 days of AngII infusion was utilized to allow for examining the 
effects of COX-2 inhibition during early-stage of AAA progression. Although celecoxib 
treatment from day 5 to day 14 of the AngII infusion resulted in a trend for reduced AAA 
incidence, the difference was not statistically significant (Figure 3.1A). As compared to 
the 40% AAA incidence in mice on control diet at the 14 day time-point, AAA incidence 
was increased to 71% in control mice when analyzed after 21 days of AngII infusion 
(Figure 3.1B). Analysis of this 21 day time-point showed that celecoxib administration 
significantly reduced AAA incidence when treatment began on day 5 of the AngII 
infusion, as compared to mice on control diet (Figure 3.1B). As compared to mice on 
control diet infused with AngII for 28 days, celecoxib treatment from day 5 to day 28 of 
the infusion also significantly reduced AAA incidence (Figure 3.1C). These findings 
indicate that COX-2 inhibitor treatment was effective for attenuating AAA progression 
when treatment was begun after the disease had been initiated. 
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Figure 3.1: Effectiveness of celecoxib on AAA incidence after beginning AngII 
infusion. AAA incidence of mice on control or celecoxib diet was determined after (A) 
14 days; (B) 21 days; and (C) 28 days of AngII infusion. Data represented as percent 
incidence; n ≥ 8; ** represent p value < 0.01; Chi-squared test. 
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3.2. AAA severity is effectively attenuated by COX-2 inhibitor treatment begun 
after initiation of the disease  
The external aortic diameter of the supra-renal region of the aorta was measured 
as a quantitative method of analyzing the effect of celecoxib treatment on AAA severity. 
Abdominal aortas were categorized as no AAA with diameters < 1.5 mm, as Type 1 
AAA with diameters from 1.5 – 1.9 mm, or Type 2 AAA with diameters ≥ 2 mm. As 
shown in Figure 3.2A, celecoxib treatment from day 5 to day 14 of the AngII infusion did 
not significantly alter the mean aortic diameter and resulted in a level of AAA severity 
similar to mice on control diet (Figure 3.2B). In contrast, analysis of abdominal aortas 
after 21 days of AngII infusion shows a significant reduction in mean aortic diameter in 
mice treated with celecoxib (Figure 3.3A). The reduction in mean aortic diameter in mice 
after 21 days of AngII infusion resulted from decreased incidence of both Type I and 
Type II AAAs (Figure 3.3B). Similar results were obtained after 28 days of AngII 
infusion, when celecoxib treatment started on day 5 of the infusion significantly 
decreased the mean aortic diameter (Figure 3.4A), which resulted from a reduced 
incidence of both Type 1 and Type 2 AAAs (Figure 3.4B). Therefore, COX-2 inhibitor 
treatment effectively reduced the severity of AAAs during progression of the disease.  
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Figure 3.2: Effectiveness of celecoxib on AAA severity 14 days after beginning 
AngII infusion. External abdominal aortic diameter of mice on control or celecoxib diet 
was determined after 14 days of AngII infusion (A). Data represented as mean ± SEM; n 
≥ 8; unpaired t-test. AAA severity of mice on control or celecoxib diet was determined by 
classification as Type 1 or Type 2 AAAs after 14 days of AngII infusion (B). Data 
represented as percent incidence; n ≥ 8.  
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Figure 3.3: Effectiveness of celecoxib on AAA severity 21 days after beginning 
AngII infusion. External abdominal aortic diameter of mice on control or celecoxib diet 
was determined after 21 days of AngII infusion (A). Data represented as mean ± SEM; n 
≥ 8; “**” represent p value < 0.01; Unpaired t-test. AAA severity of mice on control or 
celecoxib diet was determined by classification as Type 1 or Type 2 AAAs after 21 days 
of AngII infusion (B). Data represented as percent incidence; n ≥ 8.  
 
 
55 
 
Figure 3.4: Effectiveness of celecoxib on AAA severity 28 days after beginning 
AngII infusion. External abdominal aortic diameter of mice on control or celecoxib diet 
was determined after 28 days of AngII infusion (A). Data represented as mean ± SEM; n 
≥ 8; “*” represent p value < 0.05; Unpaired t-test. AAA severity of mice on control or 
celecoxib diet was determined by classification as Type 1 or Type 2 AAAs after 28 days 
of AngII infusion (B). Data represented as percent incidence; n ≥ 8.  
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3.3. COX-2 inhibitor treatment protects against AngII-induced aortic rupture  
The AngII infusion model of AAAs results in an increased incidence of aortic 
rupture and resulting mortality.[4] In the current study, we performed necropsy on mice 
that died prior to completion of the 28-day AngII infusion and utilized the detection of a 
hemorrhage adjacent to the aorta as confirmation of a ruptured aorta. As is evident from 
the survival curve (Figure 3.5A), the death of the mice from aortic rupture occurred 
throughout the AngII infusion. The time to death during the course of AngII infusion was 
observed to be delayed in the celecoxib treated mice. Celecoxib treatment also 
significantly decreased the overall incidence of mortality that occurred during the AngII 
infusion (Figure 3.5B). Therefore, COX-2 inhibitor treatment initiated 5 days after 
beginning the AngII infusion effectively protected mice from aortic rupture and death. 
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Figure 3.5A: Effect of celecoxib on time to death of AngII-infused mice. The effect of 
control or celecoxib treatment started 5 days after beginning AngII infusion was 
determined on survival of mice after 28 days of AngII infusion. Data represented as 
percent survival; n ≥ 19.  
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Figure 3.5B: Effectiveness of celecoxib on AngII-induced aortic rupture and death. 
The effect of control or celecoxib treatment started 5 days after beginning AngII infusion 
was determined on incidence of aortic rupture in mice after 28 days of AngII infusion. 
Data represented as percent incidence; n ≥ 19; “*” represent p value < 0.05; Chi-squared 
test. 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
Discussion 
 
AAAs are a chronic condition with a prevalence of approximately 5% in men 65 
years or older.[14] AAAs often progress slowly over years or decades leading to 
increased susceptibility of aortic rupture later in life.[4] Although these AAAs are readily 
identified by non-invasive imaging methods even at an early stage of development, most 
are below the size threshold required for surgical intervention.[40, 161] Human studies 
examining the progression of AAAs show a predictable annual growth rate with the 
majority of early AAAs eventually requiring surgery, which is associated with a 
significant risk of mortality.[4, 6, 160] However, currently there are no pharmacological 
treatments to slow progression of this disease.  
The AngII infusion model of AAAs was established by Daugherty et al. as being 
highly effective in producing AAAs in apoE (-/-) mice when infused with 1000 
ng/kg/min of AngII for 28 days, and has since then been a widely accepted model for 
characterizing AAA development.[51] Similar to the apoE (-/-) mice, studies from our 
laboratory, using this model, have shown that AngII infusion induces a high incidence of 
AAAs in mice of a non-hyperlipidemic background as well.[55] In the current studies, we 
have utilized this AngII infusion model in non-hyperlipidemic mice to characterize the 
role of COX-2 during AAA progression.  
The aim of the current study was to characterize a potential treatment to attenuate 
AAA progression after the disease has been initiated. Aneurysmal pathology has been 
shown to occur as early as 48 hours after beginning AngII infusion, as manifested by 
medial macrophage infiltration into the suprarenal aorta. This was accompanied by 
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disruption of elastin fibers at these sites of macrophage accumulation.[54] We have also 
previously reported that development of early AAAs is observed in mice 3 days after 
beginning AngII infusion.[56] Therefore, the AngII-induced AAA model results in a 
robust and rapid development of aneurysmal pathology during the first few days of AngII 
infusion. 
In the current study, we examined the effect of beginning treatment with the 
COX-2-selective inhibitor, celecoxib, after the development of early aneurysmal 
pathology in mice. We found that beginning celecoxib treatment after 5 days of AngII 
infusion significantly decreased AAA incidence as compared to mice on control diet, 
after completion of a 28 day infusion. The 28 day AngII infusion model has been shown 
to result in AAAs of varying severity as determined by the mean external diameter of the 
abdominal aorta.[56] The current studies show that compared to control mice, celecoxib 
treatment significantly reduced the mean external diameter of the abdominal aorta. The 
reduction in mean aortic diameter in mice resulted from decreased incidence of both 
Type I (external aortic diameter of 1.5 – 1.9 mm) and Type II AAAs (external aortic 
diameter of ≥ 2 mm). Thus, celecoxib, administered during AAA progression, effectively 
reduced both incidence and severity of AAAs when analyzed after 28 days of AngII 
infusion. 
Our previous studies have shown that AAA incidence increases during the course 
of the 28 day AngII infusion.[56] To identify the stage of AAA progression when 
celecoxib produces its benefit, we analyzed the effect of COX-2 inhibition at time-points 
prior to completion of the 28 day infusion. When analyzed 14 days after AngII infusion, 
celecoxib treatment, started 5 days after the infusion, reduced the incidence of AAAs 
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compared to the control mice, although this difference was not statistically significant. 
The AAA incidence in the control mice at this 14 day time-point was considerably lower 
(40%) than those observed at later time-points of 21 (71%) and 28 days (82%). 
Therefore, the lack of statistical significance for the effect of celecoxib treatment after 14 
days of AngII infusion may have resulted from limited disease development in the 
control mice at this early time-point. With the higher AAA incidence (71%) in control 
mice after 21 days of AngII infusion, celecoxib treatment did significantly reduce AAA 
incidence at this time-point. These results suggest that beginning COX-2 inhibitor 
treatment, after initiation of the disease, effectively attenuates AAA expansion during 
progression of the disease. 
The primary clinical significance of AAA development is the increased 
susceptibility of aortic rupture. AAAs are characterized by extensive remodeling of the 
vessel wall and eventual degradation of the extracellular matrix leading to a ruptured 
aorta. Aortic rupture associated with AAAs is reported to result in approximately 90% 
mortality in humans.[5] The AngII-induced mouse model of AAAs is also associated 
with an increased incidence of aortic rupture and resulting death. Saraff et al. were the 
first to report that approximately 10% of the mice treated with AngII died due to ruptured 
aorta during early AngII infusion.[54] In another study utilizing the AngII infusion 
model, approximately 25% of the mice were reported to have died due to hemorrhage 
around the aortic arch as well as the suprarenal aorta during the first 7 days of AngII 
infusion.[166] However, using the same model, AAA studies by Wang et al. have 
reported sudden death of mice due to rupture of the abdominal aorta for longer periods of 
AngII infusion.[163] Similarly, in the current study, we observed aortic rupture and 
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resulting death in mice on control diet throughout the AngII infusion. Previous studies 
have shown that decreased AAA formation in mice is associated with an improved 
survival by reducing AngII-induced aortic rupture. Genetic deletion of mPGES-1 was 
found to reduce AAA development in mice and decrease both the incidence as well as the 
time to aortic rupture.[163] Recently, treatment with rosiglitazone has been reported to 
reduce AngII-induced aortic rupture in apoE (-/-) mice.[167] Similarly in the current 
study, celecoxib treatment reduced the rate of mortality during the course of AngII 
infusion, thereby resulting in a significant decrease in the overall incidence of aortic 
rupture and death. Thus, in addition to effectively reducing AAA incidence, COX-2 
inhibition also significantly improves survival following AngII infusion in mice.  
Several other studies have been carried out using the AngII infusion model in 
mice to identify potential pharmacotherapies for AAAs. Similar to our previous findings 
with celecoxib, pre-treatment with fasudil, a Rho-kinase inhibitor, as well as simvastatin, 
a HMG-CoA reductase inhibitor was found to reduce AngII-induced AAA formation in 
mice.[56, 66, 164] An additional study showed the usefulness of a JNK inhibitor in 
reducing AAAs when treatment was initiated after completion of the AngII 
infusion.[168] Further studies show that pharmacological antagonism of the leukotriene 
(LT) B4 receptor, BLT1, concomitant with AngII infusion, reduces AngII-induced 
AAAs, although, administration of the drug post AngII infusion failed to protect the mice 
from AAAs[165]. However these studies using the AngII infusion model indicate the 
dearth of pharmacological inhibitors which limit AAA progression after initiation of the 
disease. In our current studies, we show for the first time, that treatment with a COX-2-
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selective inhibitor, initiated after early development of the disease, is effective in 
attenuating the progression of AngII-induced AAAs in mice. 
Previous studies have utilized hyperlipidemic mice to investigate the use of 
genetic deletion or pharmacological inhibition of involved molecules in reducing AAAs. 
However, expansion of small AAAs in humans has been shown to be independent of 
their cholesterol levels.[13] Thus, our current finding that celecoxib displayed 
effectiveness in attenuating AngII-induced AAAs in a non-hyperlipidemic mouse model 
may be relevant to using celecoxib in human studies in the absence of atherosclerosis. 
Chronic administration of both non-selective and COX-2-selective inhibitors has 
been associated with increased adverse cardiovascular events.[118, 169] Although the 
COX-2-selective inhibitor rofecoxib was withdrawn from the market due to increased 
adverse cardiovascular events, the level of risk for developing these adverse effects is 
considered lower with celecoxib use and comparable to other NSAIDs.[123, 170, 171] 
While there has also been considerable interest in identifying effective anti-inflammatory 
agents which lack these adverse cardiovascular effects, the therapeutic potential of 
medications which inhibit novel targets downstream of COX-2 is not known.[172] 
Hence, our current findings describing the effectiveness of celecoxib in an AAA model, 
together with the lack of approved medications, emphasize the need for further studies to 
evaluate celecoxib as a potential treatment for AAAs.  
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CHAPTER 4 
 
COX-2 CONTRIBUTES TO INCREASED SUSCEPTIBILITY OF ABDOMINAL 
AORTA TOWARDS ANEURYSM FORMATION IN MICE 
 
Introduction 
 
The aorta can be divided into three broad regions: the arch, thoracic and 
abdominal regions. In humans, the most common location for aneurysm development is 
the abdominal region of the aorta.[161, 173] These are known as abdominal aortic 
aneurysms (AAAs), and are specifically localized in the infra-renal abdominal aorta, i.e., 
just below the renal arteries.[Ref] A similar effect is observed in the AngII-induced 
mouse model of AAAs where the majority of aneurysm development is specific to the 
abdominal aorta.[51] Although these different regions of the aorta have diverse 
biochemical properties, the reasons as to why aneurysms are primarily localized in the 
abdominal region of the aorta, are not well-defined.[173]  
Human AAAs are characterized by both an increase in systemic inflammatory 
mediators and vascular inflammation localized in the aortic wall. Prostanoids are believed 
to be important regulators of these inflammatory processes.[4, 124, 125] Both COX-2 
and the resultant PGE2 have been found to be induced in the human aneurysmal tissue as 
compared to the normal aorta.[38, 125, 174] Using the AngII infusion model of AAAs, 
we have previously reported that genetic deficiency as well as pharmacological inhibition 
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of COX-2 can reduce AAA formation in mice.[55, 56] These reports indicate that COX-2 
plays an important role during AAA formation. 
AngII is known to increase COX-2 expression in cultured vascular smooth muscle 
cells.[78, 175-177] This increase in COX-2 expression by AngII has been found to be 
mediated by the AT1 subtype of AngII receptors.[78, 175] Expression of these AT1a 
receptors has also been reported to be higher in the abdominal region as compared to the 
thoracic region of the aorta of mice in absence of AngII infusion.[178] However, 
comparison of AT1a receptor expression in different segments of the aorta following 
AngII infusion has not been previously reported. 
Based on the above reports, we therefore hypothesized that a greater induction of 
COX-2 coupled to AT1a receptor expression contributes to the increased susceptibility of 
the abdominal aorta towards AngII-induced aneurysm formation in mice. 
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Results 
 
4.1. AngII infusion results in prolonged induction of COX-2 in the abdominal aorta 
To examine the role of COX-2 in the increased susceptibility of the abdominal 
aorta, the induction of COX-2 expression in response to AngII infusion was compared 
between the arch, thoracic and the abdominal aortic segments. In the aortic arch, the 
infusion of AngII for 3 days resulted in a significant induction of COX-2 mRNA 
expression, as compared to saline-infused mice (Figure 4.1A). In contrast, COX-2 
expression in the arch significantly decreased in response to AngII after 7 and 21 days of 
the infusion (Figure 4.1A). After 28 days of infusion, there was no significant difference 
in COX-2 expression in the aortic arch of saline and AngII -infused mice (Figure 4.1A).  
In the thoracic segment of the aorta, AngII induced a significant increase in COX-
2 mRNA expression when analyzed after 3 days of infusion (Figure 4.1B). Similar to the 
aortic arch, the initial induction of COX-2 expression in the thoracic segment was 
followed by reduced expression of COX-2 in response to 7 days of AngII infusion, with a 
statistically significant reduction observed after 21 days of infusion (Figure 4.1B). After 
28 days of infusion, COX-2 mRNA levels in the thoracic aorta of mice infused with 
AngII were not significantly different from those infused with saline (Figure 4.1B).  
Analysis of the abdominal segment of the aorta shows that AngII infusion for 3 
days significantly increased COX-2 expression, as compared to saline-infused mice 
(Figure 4.1C). In contrast to the arch and thoracic segments, 7 days of AngII infusion 
significantly increases COX-2 expression in the abdominal aorta (Figure 4.1C). The 
AngII-induced increase in COX-2 expression in the abdominal aorta continued through 
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the 21 day time-point (Figure 4.1C). After 28 days of infusion, COX-2 expression in the 
abdominal aorta was not significantly increased in response to AngII (Figure 4.1C).  
The above results for COX-2 mRNA expression in the arch, thoracic and 
abdominal aortic segments are represented in a combined graph in Figure 4.1D. Figure 
4.1D shows COX-2 mRNA levels in the three aortic segments in response to AngII 
infusion for different time-periods expressed as a percentage of saline mRNA levels 
under the corresponding condition. Saline infusion was used as the control condition for 
these experiments. Thus, Figure 4.1D shows that 3 days of AngII infusion resulted in the 
induction of COX-2 mRNA which was more than 200% of the corresponding saline 
expression in the arch and thoracic segments of the aorta. However, by 7 days of AngII 
infusion, these COX-2 mRNA levels in the arch and thoracic aorta decreased to almost 
50% of the basal levels expressed in saline-infused mice and remained lower through the 
21 days infusion time-point. At the end of 28 days of AngII infusion, the COX-2 mRNA 
expression in the arch and thoracic segments were comparable to those expressed in 
saline-infused mice. In the abdominal segment, AngII infusion for 3 days resulted in 
approximately 350 fold greater induction of COX-2 mRNA, compared to the saline-
infused mice. However, in contrast to the arch and thoracic segments, the AngII-induced 
COX-2 expression in the abdominal aorta remained higher for the 7 and 21 day time-
points as well, till approximately 150% more than saline mRNA levels after 28 days of 
infusion.  
These findings indicate that in the abdominal aorta COX-2 gene expression 
remains induced during the majority of the AngII infusion, in contrast to the transient 
induction that occurs in the arch and thoracic segments.  
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Figure 4.1A: Effect of AngII infusion on COX-2 mRNA expression in the aortic arch 
segment 
COX-2 mRNA expression was determined in the aortic arch of mice following 3, 7, 21 
and 28 days of saline or AngII infusion. COX-2 expression in the aortas of AngII-treated 
mice was standardized to corresponding saline values at each time-point. The 
housekeeping gene HPRT was used as an internal control for normalizing mRNA levels. 
Data represented as mean ± SEM; n ≥ 8; * represent p value < 0.05; *** represent p 
value < 0.001; Unpaired t-test.  
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Figure 4.1B: Effect of AngII infusion on COX-2 mRNA expression in the thoracic 
aorta segment 
COX-2 mRNA expression was determined in the thoracic aorta of mice following 3, 7, 
21 and 28 days of saline or AngII infusion. COX-2 expression in the aortas of AngII-
treated mice was standardized to corresponding saline values at each time-point. The 
housekeeping gene HPRT was used as an internal control for normalizing mRNA levels. 
Data represented as mean ± SEM; n ≥ 8; * represent p value < 0.05; ** represent p value 
< 0.01; Unpaired t-test.  
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Figure 4.1C: Effect of AngII infusion on COX-2 mRNA expression in the abdominal 
aorta segment 
COX-2 mRNA expression was determined in the abdominal aorta of mice following 3, 7, 
21 and 28 days of saline or AngII infusion. COX-2 expression in the aortas of AngII-
treated mice was standardized to corresponding saline values at each time-point. The 
housekeeping gene HPRT was used as an internal control for normalizing mRNA levels. 
Data represented as mean ± SEM; n ≥ 8; * represent p value < 0.05; Unpaired t-test.  
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Figure 4.1D: Effect of AngII infusion on COX-2 mRNA expression in the arch, 
thoracic and abdominal segments of the aorta 
COX-2 mRNA levels were expressed as percentage of expression levels in aortas of 
saline-infused mice. COX-2 expression was analyzed in the arch, thoracic and abdominal 
segments of the aorta after 3, 7, 21 and 28 days of infusion. Data represented as 
percentage of saline-infused control; n ≥ 8. 
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4.2. Comparison of COX-2 expression between the thoracic and abdominal aorta 
following AngII infusion  
With the induction of COX-2 in response to AngII infusion being greatest in the 
abdominal segment, a direct comparison of COX-2 mRNA expression between the 
abdominal and thoracic segments was performed. After 3 days of AngII infusion, there 
was an equivalent level of COX-2 mRNA between the thoracic and abdominal segments 
(Figure 4.2A). By 7 days of the AngII infusion, there was a trend for COX-2 to be greater 
in the abdominal aorta, although not statistically significant (Figure 4.2B). COX-2 
mRNA expression was significantly greater in the abdominal segment after 14 days of 
AngII infusion, as compared to thoracic aorta (Figure 4.2C). The significantly greater 
level of COX-2 expression in the abdominal aorta remained at the 21 day time-point 
(Figure 4.2D), whereas after 28 days of AngII infusion, expression returned to 
comparable levels between the two segments (Figure 4.2E). These results indicate that 
COX-2 gene expression in the abdominal aorta was significantly greater than the thoracic 
region during the majority of AngII infusion. 
 
 
 
 
 
 
 
 
 
73 
 
Figure 4.2: Comparison of COX-2 mRNA expression between thoracic and 
abdominal aortic segments. 
COX-2 mRNA expression was determined in thoracic (clear bars) and abdominal (filled 
bars) segments of the aorta of mice following (A) 3 days; (B) 7 days; (C) 14 days; (D) 21 
days and (E) 28 days of AngII infusion. Data represented as mean ± SEM; n ≥ 8; * 
represent p value < 0.05; Unpaired t-test.  
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4.3. Comparison of COX-2 protein expression between thoracic and abdominal 
aortic segments. 
To compare the expression of COX-2 protein between the thoracic and abdominal 
aortic segments, mice were infused mice with 1000 ng/kg/min AngII and sacrificed after 
14 days. The thoracic and abdominal segments of the aortas were collected and analyzed 
for COX-2 protein expression by immunohistochemistry. COX-2 protein expression was 
not observed in cells of the vascular wall of the thoracic aorta (Figures 4.3A and 4.3B). In 
contrast, abundant COX-2 expression was observed in the abdominal segment of the 
aorta (Figure 4.3C). Higher magnification of the abdominal aorta shows a concentration 
of staining for COX-2 around the nuclei of medial smooth muscle cells (Figure 4.3D). 
These findings indicate that after AngII infusion COX-2 protein expression is readily 
detected in SMCs of the abdominal aorta but is not observed in cells of the thoracic aorta.  
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Figure 4.3: Comparison of COX-2 protein expression between thoracic and 
abdominal aortic segments. 
Immunohistochemical analysis of COX-2 protein in thoracic aorta with (A) 100X and (B) 
400X magnification and in abdominal aorta with (C) 100X and (D) 400X magnification. 
Brown staining indicates detection of COX-2 protein. 
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4.4. Abdominal aorta shows greater AngII receptor expression than the thoracic 
aorta  
To account for increased levels of COX-2 induction in the abdominal aorta, mice 
were infused with AngII and sacrificed after 3, 7, 14, 21 and 28 days of infusion. The 
aortas were collected and the mRNA expression of the AT1a receptor was compared 
between the thoracic and abdominal segments during the course of AngII infusion. As 
shown in Figure 4.4A, after 3 days of AngII infusion, AT1a gene expression in the 
abdominal segment was significantly greater than the corresponding thoracic segment. 
After 7 days of AngII infusion, AT1a mRNA levels remained significantly greater in the 
abdominal aorta as compared to the thoracic region (Figure 4.4B). This increased AT1a 
expression was maintained at subsequent time-points of 14 days (Figure 4.4C), 21 days 
(Figure 4.4D) and 28 days (Figure 4.4E) of AngII infusion. These results indicate that 
AT1a receptor gene expression in the abdominal aorta remained significantly greater than 
expression in the thoracic region throughout the AngII infusion.  
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Figure 4.4: Comparison of AT1a mRNA expression between thoracic and 
abdominal aortic segments.  
AT1a mRNA expression was determined in thoracic (clear bars) and abdominal (filled 
bars) segments of the aorta of mice following (A) 3 days; (B) 7 days; (C) 14 days; (D) 21 
days and (E) 28 days of AngII infusion. Data represented as mean ± SEM; n ≥ 8; * 
represent p value < 0.05; ** represent p value < 0.01; *** represent p value < 0.001; 
Unpaired t-test.  
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Discussion 
In the current study, we examined the increased expression of COX-2 as a 
mechanism contributing to the increased susceptibility of the abdominal segment towards 
AngII-induced aneurysm formation in mice. Various studies have reported the induction 
of COX-2 in smooth muscle cells in response to AngII treatment. Ohnaka et al. were the 
first to show in cultured rat vascular smooth muscle cells (SMCs) that AngII markedly 
increased the expression of COX-2 mRNA in a time and dose-dependent manner.[176] In 
addition to mRNA, COX-2 protein was also found to be transiently increased by AngII in 
these cultured SMCs of rat aorta.[78] Subsequent studies with human vascular SMCs 
showed that the AngII-induced increase in expression of COX-2 involved transcriptional 
activation of the COX-2 gene.[175] More recently, Morinelli et al. have also shown up-
regulation of the COX-2 protein in response to AngII treatment.[177] However, these 
studies involved exposure of cultured aortic SMCs in vitro to an acute treatment of 
AngII. In contrast to acute exposure, a chronic infusion of AngII in mice for two weeks 
was found to significantly down-regulate COX-2 mRNA in mesenteric arteries.[179] 
Similarly, in the current studies, after the initial induction of COX-2 mRNA at the 3 day 
time-point, we observed a down-regulation of COX-2 in the arch and thoracic segments 
at later time-points during the AngII infusion. In contrast to the other segments, the 
abdominal aorta was resistant to the down-regulation and showed a prolonged induction 
of COX-2 that occurred during the majority of AngII infusion. 
To better characterize the region-specific COX-2 expression, a direct comparison 
was performed between the thoracic and abdominal aortas. We determined that COX-2 
gene expression was significantly greater in the abdominal region at both 14 and 21 days 
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after beginning the AngII infusion. No difference in COX-2 expression was observed 
between the thoracic and abdominal regions at the early 3 day time-point which may be 
attributed to both aortic segments showing significant AngII-induced COX-2 expression 
at this initial time-point. Additional analysis by immunohistochemistry revealed that 
COX-2 protein was readily detected in the smooth muscle cells of the abdominal, but not 
thoracic aorta. These observations suggest that a greater and more prolonged induction of 
COX-2 in the abdominal region may contribute to the increased susceptibility of this 
aortic segment to aneurysm progression.  
The AngII type 1 (AT1) receptor is mainly responsible for mediating the various 
physiological and pathological actions of AngII in vascular SMCs.[180] Previous studies 
have shown that the AT1 receptor contributes to AngII-induced COX-2 expression in 
vascular SMCs. Young et al. showed that pre-incubation with AT1 receptor antagonist, 
losartan, but not the AT2 receptor antagonist PD123319, attenuated AngII mediated 
increase in COX-2 mRNA in rat aortic SMCs.[78] Similar results were reported by Hu et 
al. when they showed that AngII-mediated COX-2 protein expression was also mediated 
by the AT1 receptors.[175] These previous findings with cultured SMCs suggest that the 
induction of COX-2 that was observed following AngII infusion in mice is dependent on 
AT1a receptor expression. 
In the absence of AngII infusion, the abdominal region of the aorta in mice has 
been shown to express a higher level of AT1a receptors as compared to the thoracic 
region.[178] However, comparison of AT1a receptor expression in different segments of 
the aorta following AngII infusion has not been previously reported. The current studies 
show for the first time that, in mice infused with AngII, AT1a receptor mRNA expression 
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in the abdominal aorta was significantly greater than the thoracic region throughout the 
AngII infusion. This suggests that AT1a receptor expression contributes to the increased 
susceptibility of the abdominal aorta to AngII-induced COX-2 expression. 
Thus, our current findings indicate that a greater and prolonged induction of 
COX-2, coupled to an increased expression of the AT1a receptors, leads to an increased 
susceptibility of the abdominal region of the aorta towards AngII-induced aneurysm 
formation in mice.  
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CHAPTER 5 
 
ANGII TREATMENT INDUCES CHANGE IN AORTIC SMOOTH MUSCLE 
CELL PHENOTYPE DURING AAA FORMATION IN MICE 
 
Introduction 
 
The arterial media in adults is made up of differentiated smooth muscle cells 
(SMCs) arranged in concentric layers allowing the cells to provide contractile function to 
the vessel. However, these fully differentiated cells have the capacity to undergo de-
differentiation and revert back to a synthetic and proliferative phenotype in response to 
mitogenic stimulation and vascular injury. Vascular SMC proliferation and de-
differentiation have been found to contribute to a variety of pathological processes 
including atherosclerosis, hypertension and coronary restenosis.[132-134] 
A role for altered differentiation of SMCs has recently been identified as a 
mechanism contributing to the development of thoracic aortic aneurysms. However, 
compared to AAAs, the prevalence of these thoracic aortic aneurysms (TAAs) is 
considered to be significantly lower.[161] A number of studies have suggested the role of 
phenotypic modulation of SMCs during the development of TAAs. Mutations in genes of 
a number of proteins of the SMC contractile apparatus have been reported to contribute to 
aneurysms of the thoracic aorta.[181-186] In addition, studies utilizing animal models 
have also suggested the role of altered SMC phenotype in the formation of TAAs.[187-
190] Thus, although the previous reports suggest that SMC de-differentiation is a key 
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factor in the formation of TAAs, the role of altered SMC phenotype in a model of AAAs 
has not been previously characterized.  
Chronic infusion of AngII has been widely utilized to study AAA development in 
mice.[51] Among its other effects, AngII is well known to induce proliferation of 
cultured aortic SMCs.[77-79] However, significantly less is known about the role of 
AngII in regulating the phenotypic plasticity of SMCs. Pannu et al. have recently 
reported that the expression of angiotensin-converting enzyme as well as the markers of 
Ang II-induced vascular inflammation (macrophage inflammatory protein-1alpha and 
beta) are upregulated in certain thoracic aneurysms which result from a mutation in a 
contractile protein.[186] AngII antagonism has also been shown to down-regulate 
markers of the de-differentiated phenotype of SMCs in the spontaneously hypertensive 
rat aorta.[191, 192] Thus, although proliferation of SMCs has been a well-characterized 
effect of AngII, the role of AngII in regulating the phenotype of vascular SMCs has not 
been well defined. 
With a role for altered SMC phenotype being suggested in other types of 
aneurysms, we hypothesized that AngII treatment modifies aortic SMCs to a proliferative 
or de-differentiated phenotype during AAA progression in mice. In the current studies, 
we utilized mice infused with either saline or AngII to investigate the role of AngII in 
regulating SMC phenotype in vivo, as well as characterize the phenotype of aortic SMCs 
during aneurysmal development.  
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Results 
 
5.1. Increased proliferation of aortic SMCs is not detected during AngII-induced 
AAA formation 
To investigate the role of AngII in regulating aortic SMC proliferation during 
AAA development, we utilized the BrdU labelling method, which is a highly sensitive 
and specific histological procedure for detection of proliferating cells in vivo. Following 
the implantation of saline or AngII-containing osmotic mini-pumps, mice were 
intraperitoneally injected with BrdU at a dose of 100mg/kg every 24 hours. After 7 or 14 
days of infusion, the mice were sacrificed. The abdominal segments of the aorta were 
dissected, processed and subsequently sectioned to perform analysis for cell proliferation 
by BrdU immunohistochemistry.  
Proliferating cells are evident by brown staining with an anti-BrdU antibody 
which detects BrdU that has been incorporated into DNA during S phase of cell cycle 
during proliferation. As a positive control for BrdU incorporation, skin samples were 
obtained from the BrdU-treated mice. The skin of these mice showed significant 
detection of BrdU in cells of the epidermis (Figures 5.1A-B). In contrast, in the aortas of 
the saline-treated mice, no significant labeling of SMCs with BrdU was observed 
(Figures 5.1C-D). Similar results were obtained for the AngII treatments, where no 
significant proliferation was detected in the SMCs comprising the medial layer of the 
aorta after both 7 (Figures 5.1E-F) and 14 days of AngII infusion (Figures 5.1G-H). 
These results suggest that proliferation of the SMCs of the aorta may not play an 
important role during AngII-induced AAA development in mice. 
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Figure 5.1: SMC proliferation in the abdominal aorta 
Immunohistochemical analysis of SMC proliferation in the positive control skin tissue at 
(A) 100X magnification and (B) 400X magnification, and in the abdominal aorta of 
saline-infused mice at (C) 100X magnification, and (D) 400X magnification. For AngII-
infused mice, immunohistochemical analysis of proliferating SMCs after 7 days of AngII 
infusion at (E) 100X magnification, and (F) 400X magnification, and after 14 days of 
AngII infusion at (G) 100X magnification, and (H) 400X magnification Brown staining 
indicates detection of BrdU-positive proliferating cells. 
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5.2. AngII decreases markers of a differentiated SMC phenotype 
To elucidate the role of AngII in regulating the vascular smooth muscle cell 
(SMC) phenotype, male non-hyperlipidemic mice were infused with saline, as control, or 
AngII at a dose of 1000 ng/kg/min. The mice were sacrificed after 7 days of saline or 
AngII infusion to examine SMC phenotypic changes during AngII-induced early 
aneurysmal development. The aortas were dissected and analyzed for mRNA expression 
of α-actin, SM22α and desmin, which are markers of a differentiated smooth muscle cell 
phenotype, by real-time PCR. Seven days of AngII infusion was found to significantly 
decrease the mRNA expression of α-actin (Figure 5.2A), desmin (Figure 5.2B) and 
SM22α (Figure 5.2C) in the abdominal aorta, as compared to saline infusion. These 
findings suggest that gene expression of markers of a differentiated SMC phenotype is 
significantly reduced in response to AngII infusion in mice. 
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Figure 5.2: Effect of AngII infusion on mRNA expression of markers of 
differentiated SMC phenotype. mRNA expression of (A) α-actin, (B) desmin and (C) 
SM22α was determined in the abdominal aortas of mice infused with saline or AngII for 
7 days. The housekeeping gene HPRT was used as an internal control for normalizing 
mRNA levels. Data represented as mean ± SEM; n ≥ 9; “*” represent p value < 0.05; 
Unpaired t-test.  
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5.3. AngII increases a marker of a de-differentiated vascular smooth muscle cell 
phenotype 
With AngII infusion reducing the expression of markers of a differentiated SMC 
phenotype, we examined the effect of AngII on expression of a de-differentiated 
phenotype marker. Male mice were infused with either saline, as control, or AngII at a 
dose of 1000 ng/kg/min, and sacrificed after 7 days. The aortas were dissected and 
analyzed for mRNA expression of hyaluronic acid synthase 2 (Has2), which has been 
shown to be expressed by SMCs of a de-differentiated phenotype. Compared to control, 
AngII infusion significantly increased the gene expression of Has2 in the abdominal 
aortas of mice (Figure 5.3). This finding suggests that in response to AngII treatment, 
SMCs of the aorta show increased expression of a gene that is characteristic of a 
synthetic phenotype. 
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Figure 5.3: Effect of AngII infusion on mRNA expression of a marker of de-
differentiated SMC phenotype. mRNA expression of Has2 was determined in the 
abdominal aortas of mice infused with saline or AngII for 7 days. The housekeeping gene 
HPRT was used as an internal control for normalizing mRNA levels. Data represented as 
mean ± SEM; n ≥ 9; “*” represent p value < 0.05; Unpaired t-test.  
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5.4. Characterization of SMC phenotype in the aorta during AngII-infused AAA 
development 
 
5.4.1 Aortic SMCs lose differentiated phenotype during AAA development 
To characterize the phenotype of SMCs during AAA development, mice were 
infused with either saline or AngII and sacrificed after 7 or 14 days of infusion. The 
abdominal segments of the aorta were dissected, processed and subsequently sectioned to 
perform immunohistochemical analysis for protein expression of α-actin. Abundant α-
actin expression, indicated by brown staining was observed in the medial SMCs of the 
aortas of mice treated with saline (Figures 5.4A-B). α-actin protein expression was also 
detected in the SMCs of the medial layer of the aorta of mice infuse with AngII for 7 
days (Figure 5.4C). However, analysis of the aorta at higher magnification revealed an 
initiation of aneurysmal pathology characterized by aortic dilation in response to AngII 
infusion for 7 days. Interestingly, this region of the aorta undergoing dilation, exhibited a 
distinct loss of expression of α-actin (Figure 5.4D). A similar pattern of α-actin 
expression was observed in the aortas of mice infused with AngII for 14 days. While 
abundant α-actin expression was observed in the thinner “non-aneurysm” segment of the 
aorta, (Figure 5.4E), significant α-actin expression was not detected in the region of the 
aorta developing into an aneurysm. Higher magnification of the non-aneurysmal region 
of the aorta shows a concentration of brown staining for α-actin in the SMCs comprising 
the medial layer (Figure 5.4F), which was absent in the cells comprising the growing 
aneurysm (Figure 5.4G). These findings suggest that during AngII-induced AAA 
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development in mice, the SMCs of the abdominal aorta undergo a loss of their 
differentiated phenotype.  
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Figure 5.4: α-actin protein expression in the abdominal aorta 
Immunohistochemical analysis of α-actin protein in the abdominal aorta of mice infused 
with saline at (A) 100X magnification, and (B) 400X magnification. Analysis for α-actin 
protein expression was also performed in the abdominal aorta of mice infused with AngII 
for 7 days at (C) 100X magnification, and (D) 400X magnification, and subsequently in 
mice infused with AngII for 14 days at (E) 100X magnification, and at 400X 
magnification in (F) the “non-aneurysm” region of the aorta and (G) the “aneurysm” 
region of the aorta. Brown staining indicates detection of α-actin protein. 
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5.4.2 Increased extracellular matrix production is associated with AngII-induced 
AAA development 
To further characterize aortic SMC phenotype during AngII-induced AAA 
development, mice were infused with saline or AngII and sacrificed after 7 and 14 days 
of AngII infusion. The abdominal segments of the aorta were dissected, processed and 
subsequently sectioned to perform analysis for expression of collagen and hyaluronic 
acid (HA), which are components of the extracellular matrix.  
Collagen content in the aortic tissues was evaluated by staining with Masson’s 
trichrome stain. Aortas of saline-infused mice stained red, indicating detection of smooth 
muscle cells, without any significant expression of collagen (Figure 5.5A). After 7 days 
of AngII infusion, the aortas continued to stain red in most regions, indicative of SMC 
expression, with a moderate amount of collagen also expressed in the region of the aorta 
which was characteristic of early aneurysmal pathology (Figure 5.5B) However, after 14 
days of AngII infusion, abundant collagen expression was observed in the “aneurysm” 
region of the aorta, as indicated by the blue stain (Figure 5.5C). In contrast, cells 
comprising the medial layer of the “non-aneurysm” region of the aorta stained red, 
indicating that they are SMCs.  
Further analysis of the abdominal aortas with hyaluronic acid binding protein 
(HABP) resulted in undetectable levels of HA in the saline-infused mice (Figures 5.5D-
E). The expression of HA after 7 days of AngII infusion was similar to the pattern 
exhibited by collagen, with a few cells on the outer edge of the medial layer beginning to 
show evidences of HA expression (Figures 5.5F-G). After 14 days of AngII infusion, the 
cells of the growing aneurysm were found to express large amounts of HA, as confirmed 
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by abundant brown staining (Figure 5.5H). However, HA expression was not observed in 
the medial layer of the “non-aneurysm” region of the aorta. Higher magnification of the 
abdominal aorta showed that SMCs on the outer edge of the medial layer adjacent to the 
aneurysm express HA, as indicated by the arrow in the figure (Figure 5.5I). These results 
suggest that during AngII-induced AAA development, aortic SMCs undergo phenotypic 
change to become de-differentiated and synthesize increased amounts of extracellular 
matrix.  
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Figure 5.5: Extracellular matrix production in the abdominal aorta 
Histological analysis of collagen in the abdominal aorta in mice infused with (A) saline, 
(B) 7 days of AngII infusion and (C) 14 days of AngII infusion at 100X magnification. 
Blue staining indicates detection of collagen, and red staining indicates detection of 
smooth muscle. Detection of HA in the abdominal aortas of saline-infused mice at (D) 
100X magnification, and (E) 400X magnification, in mice infused with AngII for 7 days 
at (F) 100X magnification, and (G) 400X magnification, and in mice infused with AngII 
for 14 days at (H) 100X magnification, and (I) 400X magnification Brown staining 
indicates detection of HA due to binding with HA-binding protein. 
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Discussion 
 
Vascular SMCs are highly specialized cells which exhibit considerable 
phenotypic plasticity. Alteration of SMCs from a contractile to a synthetic phenotype is 
known to play a major role in the development of several vascular diseases such as 
atherosclerosis, restenosis and hypertension. In the current studies, we show for the first 
time that, SMCs of the aorta show evidence of characteristics consistent with an altered 
phenotype during AngII-induced AAA development in mice.  
AngII is a potent mitogen and several studies have established AngII as an 
effective inducer of vascular SMC proliferation in cell culture.[77-79] However, only a 
few studies have investigated the role of AngII infusion in regulating SMC proliferation 
in vivo. Schwartz et al. were the first to show that AngII infusion in rats induces 
proliferation of the SMCs, as measured by [3] thymidine incorporation. The effect of 
AngII, however, was more pronounced in the neointimal SMCs of the injured artery, than 
in the underlying media or the SMCs of the normal arterial wall.[193] Similar results 
were obtained by the same group when AngII infusion was found to increase SMC 
proliferation of carotid and mesenteric arteries of rats, as determined by BrdU 
incorporation.[194] More recently, Schiffrin et al have also reported the induction of 
DNA synthesis by AngII in rat blood vessels.[195] Thus, although proliferation is well-
established in cultured SMCs, the role of AngII in inducing proliferation in the SMCs of 
the aorta, especially in mice, have not been well-defined. 
The current study investigated the role of AngII in inducing proliferation of aortic 
SMCs during AngII-induced AAA development in mice. Mice were infused with saline 
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or AngII for 7 or 14 days together with an i.p. injection of BrdU every 24 hours. 
Proliferation of aortic SMCs was then determined by immunohistochemical analysis of 
BrdU incorporated into the S phase of the replicating DNA. AngII infusion, for both 7 
and 14 days, was not found to induce detectable level of BrdU incorporation in the aortic 
SMCs of the mice. However, BrdU incorporation was sufficiently detected in the positive 
control skin tissue. Thus, this study shows for the first time that SMC proliferation of the 
aorta may not be a significant mechanism contributing to AngII-induced AAA 
development in mice.  
Although previous studies have reported that AngII infusion induces SMC 
proliferation, our findings suggest that SMCs of the aortas of mice may not show 
significant induction of proliferation in response to AngII treatment.[193-195] In the 
current study, proliferation of SMCs was analyzed in the abdominal region of the aorta, 
whereas a majority of the previous studies involved either a thoracic aorta or carotid 
artery after induction of vascular injury. This suggests that the effect of AngII induced 
proliferation of SMCs in animals could be more pronounced only under conditions of 
vascular injury. Moreover, mice have been reported to exhibit diminished responses to 
AngII infusion compared to rats, which could explain the differences observed with our 
AngII infusion results in mice.[196] Thus, in contrast to other vascular diseases such as 
atherosclerosis, restenosis and hypertension, SMC proliferation does not appear to play a 
significant role during AngII-induced AAA formation in mice. 
Limited evidence is available on the role of AngII during phenotypic conversion 
of SMCs. Attenuating the effect of AngII by selective antagonism of the AT1 receptor 
has been shown to restore expression of the contractile-type myosin heavy chain isoform 
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SM2 as well as the expression of calponin in the spontaneously hypertensive rat 
aorta[192, 197]. The AT1 receptor antagonist has also been found to down-regulate the 
non-muscle myosin heavy chain isoform, a marker of a de-differentiated SMC 
phenotype, in these rat aortas[191]. Recently, AngII has been reported to play an 
important role in the development of thoracic aortic aneurysms (TAAs) in humans, which 
are linked to a mutation in myosin heavy chain 11, a marker of a contractile SMC 
phenotype.[186] Thus, with findings that AngII contributes to thoracic aneurysm 
formation which is a disease where altered SMC differentiation is a causative factor, in 
the current studies, we investigated the effect of AngII infusion in modulating SMC 
phenotype in the abdominal aorta of mice.  
Mice were infused with either saline, as control, or AngII for 7 days and 
phenotypic change of the SMCs of the abdominal region of the aorta was examined by 
analyzing the changes in gene expression of markers characterizing both the contractile 
and synthetic phenotype. AngII infusion was found to significantly decrease the mRNA 
expression of α-actin, desmin and SM22α, which are well-known markers of the 
differentiated SMC phenotype, while increasing the mRNA levels of Has2, which is 
expressed by a de-differentiated SMC phenotype. These results indicate for the first time 
that 1 week of AngII infusion may affect abdominal aortic SMCs of mice to change from 
a contractile to a synthetic phenotype. 
A variety of genetic studies were carried out in humans to reveal that SMC 
contractile dysfunction can lead to thoracic aortic aneurysms (TAAs).[181] Several 
groups have shown that patients with mutations in the transforming growth factor-β 
receptor-1 and -2 have an altered SMC phenotype and are predisposed to aneurysms of 
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the thoracic aorta.[198-200] Also, mutations in genes expressed specifically by 
differentiated SMCs, including smooth muscle α-actin, myosin light chain kinase, SMC-
specific myosin heavy chain and Fibulin-4 have all been associated with increased 
susceptibility to TAAs.[182-186] In addition, phenotypic alteration of vascular SMCs has 
previously been reported to precede elastolysis in a mouse model of TAAs.[187] Owens 
et al have also shown that SMCs of the aorta have reduced expression of contractile 
proteins following the development of aneurysms induced by elastase perfusion in mice. 
This study also showed minimal detection of contractile proteins by 
immunohistochemistry in human AAAs.[188] Vascular SMCs have also been found to 
undergo remodeling from a contractile to a synthetic phenotype during progression of 
elastase-induced aneurysms in the right internal carotid artery of rabbits.[189] More 
recently, deficiency of integrin-linked kinase, a protein associated with the contractile 
phenotype of SMCs, has been reported to cause TAAs in mice.[190] Therefore, although 
a number of reports indicate a role for an altered SMC phenotype in contributing to the 
formation of aneurysms that form at locations other than the abdominal aorta, previous 
reports have not shown a role for altered SMC differentiation in contributing to the 
development of AAAs.  
With our finding that 7 days of AngII infusion in mice is associated with an 
alteration of aortic SMCs to a de-differentiated phenotype, in the current studies, we 
examined whether SMCs of the abdominal aorta could potentially change their phenotype 
during AngII-induced AAA development in mice. Mice were infused with saline or 
AngII for 7 or 14 days, and subsequently analyzed for immunohistochemical expression 
of makers of the contractile and synthetic phenotypes in the SMCs of the abdominal 
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aorta. AngII infusion was found to cause significant aneurysmal pathology with a loss of 
the differentiated phenotype as manifested by decreased expression of α-actin in the 
“aneurysmal” region of the aorta, when compared to the “non-aneurysm” region where 
no pathology was observed. Since collagen and HA are extracellular matrix components 
typically synthesized by de-differentiated SMCs, and AngII is known to stimulate 
collagen synthesis in human vascular SMCs, we also analyzed the deposition of collagen 
and HA in these abdominal aortas.[201] The AAAs were specifically found to produce 
abundant collagen and hyaluronic acid, indicating that, similar to other vascular diseases, 
the tissue composing the AAAs produces significant levels of extracellular matrix 
components known to be produced by SMCs expressing a synthetic phenotype.  
De-differentiated vascular SMCs are usually thought to have an increased rate of 
proliferation together with synthesis of ECM components, and a decrease in the 
expression of smooth muscle specific contractile proteins. However, several reports have 
suggested that differentiation and proliferation of SMCs are not mutually exclusive, and 
that factors regulating one process may not affect the other.[202] For example, vascular 
SMCs during embryogenesis and postnatal development exhibit high rates of 
proliferation as well as expression of differentiation proteins.[203, 204] Alternatively, 
some agents which inhibit vascular SMC proliferation do not affect their 
differentiation.[205] In the current studies, we found that, although SMCs of the 
abdominal aorta show evidence of an altered phenotype in response to AngII treatment, 
proliferation of these cells is largely undetected during AAA development in mice. This 
is similar to atherosclerosis where vascular SMCs in the advanced lesions are 
phenotypically modulated, but demonstrate very low levels of proliferation.[206, 207] 
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This suggests that, although considered to constitute the same synthetic phenotype, 
vascular SMCs under certain conditions may not proliferate, but retain their de-
differentiation properties. 
 Our current findings suggest that vascular SMCs of the abdominal aorta show 
evidence of reduced differentiation characteristics and revert to a more de-differentiated 
phenotype during AngII-induced AAA formation in mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Kamalika Mukherjee 2012 
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CHAPTER 6 
 
COX-2 REGULATES VASCULAR SMOOTH MUSCLE CELL PHENOTYPE 
DURING AAA DEVELOPMENT IN MICE 
 
Introduction 
 
COX-2 is known to play an important role during AAA formation in mice. Using 
an AngII-infusion model in mice, we have previously reported that genetic deficiency of 
COX-2 significantly reduces AAA formation.[56] Furthermore, we have shown that pre-
treatment with the COX-2-selective inhibitor celecoxib prior to disease initiation reduces 
AAA formation in mice.[55] As described previously in Chapter 3, we have also recently 
found that celecoxib treatment, even when begun after disease initiation, can effectively 
attenuate the progression of AAAs in mice. However, the mechanism by which COX-2 
can regulate the development of AngII-induced AAAs in mice has not been described.  
Prostaglandins (PGs) have been suggested to play a key role in regulating 
vascular SMC phenotype. Similar to their diverse pathophysiological role in health and 
disease, PGs have been reported to exhibit differential regulation of SMC phenotypic 
plasticity. Prostaglandin I2 (prostacyclin) has been shown to promote a differentiated 
phenotype of human vascular SMCs in culture.[208] In contrast, PGE2 production has 
been suggested to enhance the de-differentiation of rat aortic SMCs.[209] In addition, 
both prostacyclin analogue iloprost, as well as PGE2 have been shown to increase 
synthesis of hyaluronic acid (HA), the extracellular matrix component typically 
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expressed by SMCs of synthetic phenotype, by inducing expression of HA synthases 
Has1 and Has2 in SMCs.[210-212] More recently, the non-selective COX inhibitor 
indomethacin, and the COX-2-selective inhibitor rofecoxib have been shown to reduce 
vascular HA accumulation by inhibiting Has1 and Has2 mRNA expression in mouse 
models of atherosclerosis and neointimal hyperplasia.[213] Thus, although the role of 
COX-2 in regulating SMC phenotype is not well defined, the above studies suggest that 
PGs could be important factors in the regulation of phenotypic modulation of SMCs. 
Although there is limited data on the role of SMC phenotype on AAAs, other 
types of aneurysms have been associated with an altered phenotype of vascular SMCs. In 
addition to genetic mutations in the contractile proteins predisposing to thoracic aortic 
aneurysms and dissections, several animal models of thoracic aneurysms have suggested 
that change in SMC phenotype is an important factor contributing to the development of 
the disease[181-185, 187-190, 214]. Moreover, our data in Chapter 4 show that, in a 
mouse model of AAAs, AngII infusion can induce vascular SMCs to change from 
contractile to a synthetic phenotype during AAA development in mice.  
Based on the role of PGs in regulating the phenotype of cultured SMCs, and that 
SMC phenotypic modulation is an important phenomenon contributing to thoracic 
aneurysm formation, we hypothesized that the effectiveness of COX-2 inhibition in 
reducing AngII-induced AAA development in mice is associated with maintaining a 
differentiated phenotype of aortic SMCs. In the current studies, we utilized COX-2-
selective inhibitor celecoxib, to investigate the role of COX-2 in regulating SMC 
phenotype.  
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Results 
 
6.1. COX-2 inhibition maintains aortic SMCs in a differentiated phenotype during 
AngII-induced AAA development in mice 
 
6.1.1. COX-2 inhibition increases mRNA expression of markers of differentiated 
SMC phenotype 
To elucidate the role of COX-2 in regulating aortic SMC phenotype during AngII-
induced AAA formation, male non-hyperlipidemic mice were infused with AngII at a 
dose of 1000 ng/kg/min. Five days after AngII infusion, the mice were divided into two 
groups; one group received a control diet (normal chow diet), and the other group 
received a diet containing the COX-2-selective inhibitor celecoxib (normal chow diet 
repelleted with 1000 ppm celecoxib). The mice were subsequently sacrificed and 
abdominal aortas were collected at different time-points of AngII infusion for examining 
the effect of celecoxib at the early, intermediate and late stages of AAA development. 
The aortas were analyzed for mRNA expression of different markers of differentiated and 
de-differentiated SMCs by real-time PCR. α-actin, desmin, smooth muscle 22α (SM22α), 
calponin (Cnn1), myosin heavy chain 11 (Myh11) and smoothelin (Smtn) were used as 
contractile markers, while hyaluronic acid synthase 2 (Has2) was utilized as a marker of a 
de-differentiated SMC.  
Analysis of abdominal aortas after 14 days of AngII infusion was utilized to allow 
for examining the effects of COX-2 inhibition on SMC phenotypic change during the 
early stage of AAA development. We found that celecoxib treatment from day 5 to day 
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14 of the AngII infusion did not significantly alter the mRNA expression of any of the 
differentiated SMC markers, α-actin, desmin, SM22α, Cnn1, Myh11 and Smtn, as 
compared to the mice on control diet (Figures 6.1A-F). Thus, COX-2 inhibition with 
celecoxib had no detectable change on the expression of the SMC differentiation genes at 
this early time-point of AngII-induced AAA development in mice.  
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Figure 6.1: Effect of celecoxib on gene expression of markers of differentiated SMC 
phenotype during early AAA development. mRNA expression of (A) α-actin, (B) 
desmin, (C) SM22α, (D) calponin, (E) Myh11 and (F) smoothelin was determined in the 
abdominal aortas of mice infused with AngII for 14 days, and treated with control or 
celecoxib diet from day 5 to day 14 of AngII infusion. The housekeeping gene HPRT was 
used as an internal control for normalizing mRNA levels. Data represented as mean ± 
SEM; n ≥ 8; unpaired t-test.  
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With our early time-point analysis showing no significant difference in the 
contractile markers, we analyzed subsequent time-points of AngII infusion to elucidate 
the role of COX-2 on SMC differentiation during the intermediate and late stages of 
AAA development. The mice were thereby sacrificed after 21 and 28 days of AngII 
infusion and the abdominal aortas of the control or celecoxib-treated mice were analyzed 
for gene expression of the SMC differentiation markers. Celecoxib treatment from day 5 
to day 21 of AngII infusion was found to significantly increase the mRNA expression of 
α-actin, SM22α, Cnn1, Myh11 and Smtn, as compared to control treatment (Figures 
6.2A, 6.2C-F). Although there was a trend towards an increased expression of desmin, 
one of the earliest contractile markers, in the celecoxib treated mice than the control 
group, this difference was not statistically significant (Figure 6.2B). Thus, COX-2 
inhibition with celecoxib was found to significantly decrease the markers of SMC 
differentiation during the intermediate phase of AAA formation in mice.  
Similar results were obtained even during the late phase of AAA development, 
when abdominal aortas of mice on celecoxib diet from day 5 to day 28 of AngII infusion 
displayed a significant increase in mRNA expression of all the SMC differentiation 
markers, α-actin, desmin, SM22α, Cnn1, Myh11 and Smtn compared to the control mice 
(Figures 6.3A-F). Thus, the above findings indicate that increased differentiation of aortic 
SMCs during the intermediate and late time-points of AngII infusion is associated with 
the effectiveness of celecoxib in reducing AngII-induced AAA progression in mice.  
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Figure 6.2: Effect of celecoxib on gene expression of markers of differentiated SMC 
phenotype during the intermediate phase of AAA development. mRNA expression of 
(A) α-actin, (B) desmin, (C) SM22α, (D) calponin, (E) Myh11 and (F) smoothelin was 
determined in the abdominal aortas of mice infused with AngII for 21 days, and treated 
with control or celecoxib diet from day 5 to day 21 of AngII infusion. The housekeeping 
gene HPRT was used as an internal control for normalizing mRNA levels. Data 
represented as mean ± SEM; n ≥ 8; “*” represent p value < 0.05; “***” represent p value 
< 0.001; unpaired t-test.  
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Figure 6.3: Effect of celecoxib on gene expression of markers of differentiated SMC 
phenotype during late phase of AAA development. mRNA expression of (A) α-actin, 
(B) desmin, (C) SM22α, (D) calponin, (E) Myh11 and (F) smoothelin was determined in 
the abdominal aortas of mice infused with AngII for 28 days, and treated with control or 
celecoxib diet from day 5 to day 28 of AngII infusion. The housekeeping gene HPRT was 
used as an internal control for normalizing mRNA levels. Data represented as mean ± 
SEM; n ≥ 8; “*” represent p value < 0.05; “**” represent p value < 0.01; unpaired t-test.  
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6.1.2. COX-2 inhibition decreases mRNA expression of a marker of de-
differentiated SMC phenotype throughout AngII infusion 
To further examine the effect of COX-2 inhibition on SMC phenotypic change 
during AngII-induced AAA development, mice were infused with AngII for 14, 21 or 28 
days, and treated with either a control diet, or diet containing celecoxib, as described 
above. The abdominal aortas of these mice were then analyzed for gene expression 
changes of Has2, a marker of a synthetic SMC phenotype. Celecoxib treatment from day 
5 to day 14 of AngII infusion was found to significantly decrease the mRNA expression 
of Has2 as compared to the mice on control diet (Figure 6.4A). Thus, COX-2 inhibition 
was found to be effective in reducing a marker of a de-differentiated SMC phenotype 
even at an early stage of AAA development. Similar results were obtained at the 
intermediate time-point of AngII infusion, when, as compared to mice on control diet, 
celecoxib treatment from day 5 to day 21 of AngII infusion significantly reduced the 
mRNA expression of Has2 (Figure 6.4B). Finally, celecoxib was found to maintain its 
effectiveness till the latest stage of disease development, when Has2 mRNA levels in the 
celecoxib-treated group was significantly lower than the group on control diet after 28 
days of AngII infusion (Figure 6.4C). These results suggest that COX-2 inhibition with 
celecoxib effectively decreases the gene expression of a marker of de-differentiated SMC 
phenotype throughout the early, intermediate and late stages of AngII-induced AAA 
development in mice.  
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Figure 6.4: Effect of celecoxib on gene expression of a marker of de-differentiated 
SMC phenotype. mRNA expression of Has2 was determined in the abdominal aortas of 
mice infused with AngII for (A) 14 days, (B) 21 days and (C) 28 days, and treated with 
control or celecoxib diet beginning 5 days after AngII infusion. The housekeeping gene 
HPRT was used as an internal control for normalizing mRNA levels. Data represented as 
mean ± SEM; n ≥ 8; “*” represent p value < 0.05; “**” represent p value < 0.01; 
unpaired t-test.  
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6.1.3. COX-2 inhibition increases protein expression of a marker of differentiated 
SMC phenotype 
To evaluate the changes in protein expression of markers of SMC phenotype 
during AngII-induced AAA formation, mice were infused with AngII, as described 
above. 5 days after the AngII infusion, the mice were divided into two groups receiving 
control diet, or diet containing celecoxib. The mice were then sacrificed after 28 days of 
AngII infusion, their aortas collected and analyzed for immunohistochemical expression 
of α-actin, the specific marker for a differentiated SMC. Figure 6.5A shows a large 
aneurysm of the abdominal aorta of the control group. The aneurysmal region was 
characterized by a loss of the elastic lamina and α-actin protein expression was 
undetectable within the cells of this lesion indicating that they are not differentiated 
SMCs. However, the cells in the medial layer were found to express α-actin, as evident 
by positive brown staining (Figures 6.5A-B). In contrast to the control group, abundant α-
actin expression was observed throughout the abdominal segment of the aorta of mice on 
the celecoxib diet (Figures 6.5C-D). These findings indicate that following AngII 
treatment, α-actin protein expression is readily detected in the SMCs of celecoxib-treated 
mice aorta but is not observed in cells of the aneurysmal lesion in mice treated with a 
control diet, suggesting that COX-2 inhibition can maintain SMCs in a more 
differentiated phenotype during AngII-induced AAA development. 
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Figure 6.5: α-actin protein expression in the abdominal aorta 
Immunohistochemical analysis of α-actin protein in the abdominal aorta of mice treated 
with control diet with (A) 100X magnification, and (B) 300X magnification, and in the 
abdominal aorta of mice treated with a celecoxib diet with (C) 100X magnification, and 
(D) 300X magnification. Brown staining indicates detection of α-actin protein.  
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6.1.4. COX-2 inhibition decreases protein expression of markers of de-differentiated 
SMC phenotype 
Mice infused with AngII were treated with control or celecoxib diet beginning 5 
days after AngII infusion. 28 days after AngII infusion, the mice were sacrificed, and the 
abdominal aortas were collected to analyze for histological expression of extracellular 
matrix components collagen and hyaluronic acid (HA), as markers expressed by SMCs of 
synthetic phenotype. Abundant collagen expression was observed in the aneurysmal 
lesion in mice treated with control diet, as indicated by the blue stain (Figure 6.6A). 
However, except the thin layer of adventitia, collagen expression was largely undetected 
in the aortas of mice treated with celecoxib, with the cells staining red, indicating the 
presence of a SMC layer (Figure 6.6B). Analysis of the aortas with a HA binding protein 
revealed that significant levels of HA are synthesized by the cells within the aneurysmal 
lesion of mice treated with a control diet (Figures 6.6C-D). In contrast, a lower level of 
HA was detected in the aortas of mice treated with celecoxib (Figures 6.6E-F). Thus, 
these results suggest that COX-2 inhibition with celecoxib prevents SMCs of the aorta to 
change to a synthetic phenotype, as determined by reduced production of collagen and 
HA, during AngII-induced AAA development in mice.  
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Figure 6.6: Extracellular matrix production in the abdominal aorta 
6.6A-B: Histological analysis of collagen in the abdominal aorta in (A) control-treated, 
and (B) celecoxib-treated mice after 28 days of AngII infusion, at 100X magnification. 
Blue staining indicates detection of collagen, and red staining indicates detection of 
smooth muscle.  
6.6C-F: Immunohistochemical analysis of HA in the abdominal aorta of mice treated 
with control diet at (C) 100X magnification, and (D) 400X magnification, and in the 
abdominal aorta of mice treated with a celecoxib diet at (E) 100X magnification, and (F) 
400X magnification. Brown staining indicates detection of HA protein. 
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6.2. COX-2 deficiency reduces a marker of de-differentiated SMC phenotype during 
early aneurysmal development 
To examine the effect of deficiency of COX-2 on aortic SMC phenotype during 
the early stage of AAA development, non-hyperlipidemic COX-2 wild-type (WT) or 
COX-2 knock-out (KO) mice were infused with AngII at a dose of 1000 ng/kg/min and 
sacrificed after 7 days of AngII infusion. The abdominal aortas were then collected and 
analyzed for gene expression of markers of the SMC phenotypes by real-time PCR. 
COX-2 deficiency did not significantly alter the mRNA levels of α-actin, a marker of 
differentiated SMC phenotype, as compared to the COX-2 WT mice after 7 days of 
AngII infusion (Figure 6.7A). Similar results were obtained for desmin (Figure 6.7B) and 
SM22α (Figure 6.7C), where mRNA expression of these differentiated SMC markers 
were not found to be significantly different between COX-2 WT and KO mice. In 
contrast, mRNA levels of Has2, which is specifically expressed by a de-differentiated 
SMC, was significantly lower in COX-2 KO mice as compared to the corresponding WT 
mice, in response to AngII infusion (Figure 6.7D). These results indicate that although 
there is no detectable change in the contractile markers, COX-2 deficiency resulted in a 
decrease in the gene expression of a synthetic SMC marker during AngII-induced early 
aneurysmal development. 
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Figure 6.7: Effect of COX-2 deficiency on gene expression of markers of SMC 
phenotypes. mRNA expression of (A) α-actin, (B) desmin, (C) SM22α and (D) Has2 
was determined in the abdominal aortas of COX-2 WT or COX-2 KO mice infused with 
AngII for 7 days. The housekeeping gene HPRT was used as an internal control for 
normalizing mRNA levels. Data represented as mean ± SEM; n ≥ 9; “**” represent p 
value < 0.01; Unpaired t-test.  
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Discussion 
 
Phenotypic modulation of SMCs is critical in regulating vascular function in 
various cardiovascular disease conditions.[128] Our results, as described in Chapter 4, 
describe for the first time that, in response to AngII treatment, aortic SMCs change to a 
de-differentiated phenotype during AAA development in mice. We have also shown that 
genetic or pharmacological inhibition of COX-2 attenuates AngII-induced AAA 
formation in mice.[55] The current studies were carried out to elucidate a potential 
mechanism by which COX-2 regulates the development of these AAAs in this AngII 
infusion mouse model.  
PGs are known to be key regulators of SMC phenotype. Bricaud et al. were the 
first to report the association between PGs and SMC phenotype, when they showed that 
phenotypically modified SMCs synthesize more prostacyclin than contractile 
SMCs.[215] This was followed by a study where exogenously added PGE1, which is 
thought to have biological properties similar to prostacyclin by binding to the PGI2 
receptors, IP, stimulated SMCs to change from a contratile to a synthetic phenotype.[216] 
However, the results derived in this study were based only on morpholological 
characterization of the cells in culture, without analysis of any of the proteins known to 
characterize the different phenotypes of SMCs. In addition, apart from binding to the IP 
receptors, PGE1 is known to act as a ligand for all the PGE2 receptors, EP1, EP2, EP3 and 
EP4 as well, suggesting that this effect of PGE1 on SMC phenotype can be different from 
those observed with prostacyclin, due to activation of the EP receptors.[99] More 
recently, the prostacyclin analog iloprost was found to induce differentiation of human 
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vascular SMCs by increasing the mRNA and protein expression of smooth muscle 
specific differentiation markers including α-actin, calponin, h-caldesmon and smooth 
muscle specific myosin heavy chain, as well as changing the morphology of the 
cells.[208] Thus, localized release of PGI2 from the endothelial cells has been suggested 
to exhibit its cardioprotective effect by a paracrine stimulation of vascular SMCs to a 
contractile phenotype.[217, 218] In contrast, another vasodilatory prostaglandin, PGE2 
was reported to enhance the de-differentiation of vascular SMCs by increasing PLA2 
secretion, and disorganization of α-actin fibers.[209] While PLA2 was utilized in this 
study to characterize de-differentiated SMCs, it has not been shown previously to be a 
marker of synthetic SMC phenotype. Furthermore, in this report, no other established 
markers of the differentiated phenotype were shown to be down-regulated to analyze the 
role of PGE2 in SMC de-differentiation. Therefore, the role of PGs in regulating SMC 
differentiation is not well defined. 
HA is an extracellular matrix component typically expressed by SMCs of the 
synthetic phenotype. Studies with human vascular SMCs show that PGE2 contributes to 
HA synthesis by inducing the HA synthases Has1 and Has2.[210-212] The induction of 
HA has been shown to be COX-2 dependent, as treatment of the cells with a high dose of 
a COX-2 specific inhibitor, etoricoxib was found to inhibit the expression of Has2.[211] 
In contrast to the previous reports describing the induction of a differentiated phenotype 
of SMCs by prostacyclin, the prostacyclin analogue, iloprost, is also found to induce the 
expression of both Has1 and Has2 in human vascular SMCs.[208, 210-212] Thus, 
although the above studies suggest that the phenotypic modulation of cultured SMCs can 
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be altered by addition of exogenous PGs, the role of endogenous PGs in regulating SMC 
phenotype is not clear. 
In mouse models of atherosclerosis and neointimal hyperplasia following vascular 
injury, Fischer et al., recently reported the effectiveness of indomethacin and rofecoxib in 
decreasing HA accumulation by regulating Has1 and Has2 mRNA expression.[213] This 
is probably the only in vivo study which has been published describing the role of 
cyclooxygenases in regulating the expression of HA and its synthases. However, 
although HA has been associated with a synthetic phenotype, the role of the COX 
isoforms in regulating other markers of SMC differentiation was not examined. 
Moreover, while indomethacin is a non-selective inhibitor of both COX-1 and COX-2, 
the cardiovascular risk of COX-2-selective inhibitor, rofecoxib is a major concern. 
However, these findings suggest a role of COX-2-dependent regulation of SMC 
phenotype in vascular remodeling including neointimal hyperplasia and atherosclerosis. 
Thus, it emphasizes the necessity to identify additional animal models of cardiovascular 
disease for further examination of the role of COX-2 in regulating SMC phenotype in 
vivo.  
In the current studies, we utilized the AngII induced AAA model to investigate 
the role of COX-2 in regulating SMC phenotyope at different stages of the disease. To 
elucidate the role of COX-2 in regulating SMC phenotype during the early stage of AAA 
development, we treated COX-2 WT and COX-2 KO mice with AngII for 7 days and 
analyzed the abdominal aortas for changes in gene expression of markers of both 
contractile and synthetic SMC phenotypes. Compared to WT mice, COX-2 deficiency 
was found to significantly decrease the mRNA expression of Has2 which characterizes 
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de-differentiated SMC phenotype. However, the mRNA levels of the differentiation 
markers such as α-actin, desmin and SM22α were not significantly altered between the 
aortas of COX-2 WT and KO mice. We also examined the effect of COX-2-selective 
inhibitor celecoxib on the gene expression of the SMC phenotypic markers at the early 
stage of AAA development. Similar to the knockout data, after 14 days of AngII infusion, 
mice, treated with a diet containing COX-2-selective inhibitor celecoxib initiated 5 days 
after the infusion, displayed no significant change in mRNA expression of the contractile 
markers, as compared to mice on control diet. In contrast, Has2 mRNA expression in the 
abdominal aorta was significantly decreased by treatment of mice with celecoxib from 
day 5 to day 14 of AngII infusion, compared to control treated mice. Thus, the current 
results indicate that genetic or pharmacological inhibition of COX-2 decrease the 
expression of a marker of de-differentiated SMC phenotype, but have no effect on the 
smooth muscle specific differentiation markers during the early phase of AngII-induced 
AAA development in mice.  
We also analyzed the regulation of COX-2 of SMC phenotype during the later 
stages of AAA progression. In these studies, mice were infused with AngII, and treated 
with control or celecoxib diet beginning 5 days after AngII infusion. The mice were then 
sacrificed after an intermediate time-point of 21 days, or a late time-point of 28 days of 
AngII infusion, and the abdominal aortas were analyzed for mRNA expression of 
contractile and synthetic markers of SMC phenotype. After both 21 and 28 days of AngII 
infusion, COX-2 inhibition was found to significantly increase the mRNA expression of 
the SMC specific contractile markers in the abdominal aorta, as compared to those of 
control treated mice. In contrast, at both of these time-points, celecoxib treatment 
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prevented modification to a de-differentiated SMC phenotype by significantly reducing 
the mRNA levels of Has2, compared to the control mice. Thses results indicate that 
COX-2 inhibition at both the intermediate (day 21) as well as the late stage (day 28) of 
AAA development is effective in increasing the gene expression of the contractile 
markers, while reducing that of the synthetic phenotype.  
Additional analysis of the abdominal aortas by immunohistochemistry after 28 
days of AngII infusion revealed that abundant α-actin protein was detected in the medial 
layer of the celecoxib-treated mice, but not in the aneurysmal lesions of the control 
group. The medial layer in the aortas of the control mice however, continued to express 
α-actin. In particular, higher expression of α-actin was observed in the medial layer on 
the distal side of the vessel, opposite to the lesion, while the medial cells adjacent to the 
lesion were found to express a lower level of the protein, as indiacted by a lighter 
staining. This could be potentially explained by the gradual loss of the medial SMC layer, 
as evident by a decrease in expression of contractile markers, to assume a more de-
differentiated phenotype. A recent study has described the correlation between medial 
elastin dissection and aortic motion resulting in the asymmetric expansion of AngII-
induced AAAs in mice.[219] Thus, in the current studies, the reduced detection of medial 
α-actin on the side of the aorta expanding towards the lesion might suggest an inherent 
difference between the medial cells on either side of the aorta. The accumulation of 
extracellular matrix components including collagen and hyaluronic acid was also 
decreased in the aorta of mice that showed reduced AAA development from celecoxib 
treatment. Thus, these results suggest that COX-2 inhibition is effective in hindering 
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phenotypic alteration, and thereby maintaining the aortic SMCs in a differentiated 
phenotype during AngII-induced AAA progression in mice.  
Our current results indicate that during the early stage of AngII-induced AAA 
progression, COX-2 inhibition modified only the de-differentiation marker, Has2, while 
both the contractile as well as the synthetic markers were significantly altered during the 
intermediate as well as the late stage of the disease. Although no studies have been 
reported on the temporal expression of the contractile versus the synthetic markers in 
vascular SMCs, these results suggest that this COX-2-dependent change in phenotype of 
SMCs of the aorta during AAA progression may be associated with an induction of cell 
de-differentiation prior to loss of the contratile phenotype.  
The above findings suggest that COX-2 inhibition attenuates AngII-induced AAA 
progression in mice by maintaining aortic SMCs in a differentiated phenotype. The 
genetic deficiency of microsomal prostaglandin E synthase-1 (mPGES-1), which 
contributes to PGE2 synthesis downstream of COX-2, has been reported to reduce AngII-
induced AAA formation.[163] However, although PGE2 has been suggested to alter 
SMCs to a synthetic phenotype, the role of mPGES-1 in regulating SMC phenotype 
during AngII-induced AAA formation has not been reported.[209] The phenotypically 
modified SMCs are known to synthesize a large amount of HA in atherosclerotic lesions 
and neointima development following vascular injury.[220] In addition, our current 
findings, as shown previously in Chapter 5, indicate increased production of HA 
following AAA development in mice. Has2 is the major isoform among HA synthases 
which is induced by PGE2 in vascular SMCs.[151, 211] We also show in our current 
results that the induction of Has2 during AAA formation is regulated by COX-2. These 
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findings suggest that mPGES-1-derived PGE2 could play an important role in regulating 
SMC phenotype during AngII-induced AAA development in mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Kamalika Mukherjee 2012 
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CHAPTER 7 
GENERAL DISCUSSION 
 
7.1. Summary and conclusions 
The primary objectives of the current studies were: (1) to determine if COX-2 
inhibition with celecoxib can attenuate the progression of AngII-induced AAAs in mice, 
when treatment is begun after initiation of the disease, (2) to explain the reasons 
contributing to the increased susceptibility of the abdominal region of the aorta towards 
AngII-induced aneurysm formation in mice, and (3) to elucidate the mechanisms by 
which COX-2 regulates the development of AngII-induced AAAs in mice. 
The first studies were carried out to investigate the role of COX-2 in AngII-
induced AAA development, as described in Chapter 2. We infused mice with AngII, and 
after 5 days of AngII infusion, treated them with a control diet, or a diet containing the 
COX-2-selective inhibitor celecoxib. The AngII-induced AAA model is characterized by 
a rapid development of aneurysmal pathology within 3 days of AngII infusion.[54, 56] 
Thus, introducing the control and celecoxib diets after 5 days of AngII infusion ensured 
that COX-2 inhibition was begun after the initial development of the disease. The mice 
were subsequently sacrificed at different time-points during the AngII infusion to 
determine the effect of celecoxib on AAA progression. Celecoxib treatment from day 5 to 
day 14 of AngII infusion was found to produce a trend towards decreased incidence of 
AAAs, as compared to mice treated with the control diet. However, as the COX-2 
inhibitor treatment was extended through the 21 and 28 day time-points of AngII 
infusion, celecoxib treatment significantly reduced the incidence of AAAs, compared to 
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the control mice. COX-2 inhibition was also found to effectively reduce the severity of 
the AAAs formed after both 21 and 28 days of AngII infusion. Of particular importance 
was the fact that celecoxib treatment from day 5 to day 28 of AngII infusion effectively 
protected the mice from aortic rupture and death. In summary, COX-2 inhibition with 
celecoxib, begun after the disease initiation, was effective in improving survival and 
attenuating the progression of AngII-induced AAAs in mice. 
The following studies were carried out to determine mechanisms contributing to 
the increased susceptibility of the abdominal region of the aorta towards AngII-induced 
aneurysm development, as described in Chapter 3. Mice were infused with saline, as 
control, and AngII, following which gene expression changes in the arch, thoracic and 
abdominal segments of the aorta were analyzed at different time-points after AngII 
infusion. AngII treatment resulted in a prolonged induction of COX-2 mRNA in the 
abdominal aorta throughout the infusion period, in contrast to the transient induction 
observed in the arch and thoracic segments. A direct comparison revealed that COX-2 
gene expression in the abdominal segment was significantly greater than the thoracic 
region during the majority of AngII infusion. Moreover, in contrast to the thoracic region, 
COX-2 protein was readily detected in the smooth muscle cells of the abdominal aorta. 
Furthermore, compared to the thoracic region, mRNA expression of the AngII receptor 
AT1a was found to be significantly greater in the abdominal segment throughout the 
AngII infusion. In summary, a greater and prolonged induction of COX-2, coupled to an 
increased expression of the AT1a receptors, was found to contribute to the increased 
susceptibility of the abdominal region of the aorta towards AngII-induced aneurysm 
formation. 
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The final studies were carried out to elucidate the mechanisms by which COX-2 
regulated the development of AngII-induced AAAs in mice. We first set out to 
characterize the phenotype of aortic smooth muscle cells (SMCs) during AngII-induced 
AAA development, as described in Chapters 3. Mice were infused with saline, as control, 
and AngII, to investigate the role of AngII in regulating SMC phenotype during AAA 
formation. Increased proliferation of the SMCs was not detected during AngII-induced 
AAA development. However, AngII infusion was found to significantly decrease the 
mRNA expression of the markers of a contractile phenotype, while increasing a marker 
of the synthetic phenotype. In addition, cells of the aneurysmal lesion were found to 
undergo a loss of their differentiated phenotype, as evident by decreased α-actin protein 
expression, and synthesized large amounts of extracellular matrix components, 
characteristic of a de-differentiated phenotype. Further studies were carried out to 
determine if this change in SMC phenotype during AngII-induced AAA development 
was regulated by COX-2, as described in Chapter 4. COX-2 inhibition with celecoxib, 
begun 5 days after the AngII infusion, was found to significantly increase the mRNA and 
protein expression of the markers of contractile SMC phenotype during the intermediate 
and late stages of AAA development, while reducing the markers of the synthetic 
phenotype. In summary, COX-2 inhibition was found to effectively hinder phenotypic 
alteration, and thereby maintain the aortic SMCs in a differentiated phenotype during 
AngII-induced AAA progression in mice. 
In conclusion, our findings suggest that COX-2 plays an important role in AAA 
development in mice, and inhibition of COX-2 with celecoxib attenuates AAA 
progression by maintaining a differentiated phenotype in aortic smooth muscle cells. 
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7.2. Clinical relevance and future directions 
Abdominal aortic aneurysm (AAA) is a significant health problem, and is 
currently the 10th leading cause of death in men aged over 55 years.[1, 2] Small AAAs 
are known to progress at a relatively constant rate over years, with the majority achieving 
clinically significant severity that results from increased susceptibility of rupture later in 
life.[4, 13] Currently, there are no pharmacological treatments available for AAAs, with 
open or endovascular surgical repair being the only options to prevent an impending 
aortic rupture. However, surgery for AAAs is associated with its own significant risk of 
mortality.[6] With recent advances in non-invasive imaging methods that are used for 
screening against a variety of conditions, a significant number of patients with AAAs are 
being identified. Almost 90% of these detected AAAs are small AAAs, and surgical 
repair is not recommended until they attain a diameter of 5.5 cm.[221] The early 
detection of small AAAs would allow for therapeutic intervention to prevent AAA 
expansion should an effective pharmacological treatment be identified.  
One of the primary goals of the current study was to identify a therapeutic 
strategy which could potentially limit the expansion of AAAs after they are detected. Our 
studies show that treatment with the COX-2-selective inhibitor celecoxib, begun after the 
disease initiation, effectively attenuates AngII-induced AAA progression in mice. We 
have previously reported that pre-treatment of the mice with celecoxib, prior to disease 
initiation, reduces AAA formation.[55] Moreover, AngII-induced AAAs were not 
detected in mice genetically deficient in COX-2.[56] Although the above studies were the 
first to emphasize the importance of COX-2 in AngII-induced AAA development, the 
role of COX-2 in contributing to AAA progression was not examined. Our current results 
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are more relevant to the identification of future treatments for AAAs because they 
indicate that celecoxib is efficacious in limiting the expansion of the disease after it is 
initiated.  
In addition to the inhibition of COX-2, the AngII infusion model in mice has been 
utilized to investigate a variety of methods with the potential to reduce AAAs. However, 
in majority of these studies, the efficacy of the agents was shown to occur with a pre-
treatment regimen where administration of the agent was first started before initiation of 
the disease.[66, 164] In addition, some of the agents which were shown to be beneficial 
following this pre-treatment regimen were not found to produce similar effectiveness in 
reducing AAAs when treatment was started after disease initiation.[165] Thus, the above 
reports further emphasize the importance of our current studies in the identification of 
future AAA treatments, because they describe for the first time the effectiveness of COX-
2 inhibition in attenuating AAA progression, when treatment is initiated after early 
development of the disease. 
The AngII infusion model of AAAs displays multiple characteristics of human 
AAAs, and thus has been widely utilized to characterize the mechanisms contributing to 
the progression of the disease.[54] One of the advantages of the AngII model has been its 
association with aortic rupture and death, a characteristic that is similar to the human 
disease.[54, 163, 166] In our current studies we show that COX-2 inhibition with 
celecoxib, begun after disease initiation, significantly reduces the incidence as well as the 
rate of aortic rupture in mice. The improvement in survival that results from the 
inhibition of COX-2 in the AngII-induced AAA model is a significant outcome and 
would be a requirement of future pharmacological treatment for AAAs.  
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Although AAA has been traditionally considered to be a consequence of 
atherosclerosis, recent evidences suggest that the atherosclerotic burden of a patient is not 
associated with increases in AAA growth.[13, 18] Thus, our finding that celecoxib 
displays its effectiveness in reducing AngII-induced AAAs in a nonhyperlipidemic 
mouse model may be clinically important, as it indicates that celecoxib directly 
influences AAA formation in the absence of hyperlipidemia, and suggests the potential 
effectiveness of COX-2 inhibition independent of atherosclerosis development.  
Results from our current studies show that an increased expression of COX-2, 
associated with higher AT1a receptor expression, contributes to the increased 
susceptibility of the abdominal aorta towards aneurysm formation. The AT1 receptors are 
known to play an important role during AngII-induced AAA development in mice. 
Antagonism of the AT1 receptor with losartan has been reported to reduce AAA 
formation in mice.[87] More recently, the endothelial cell-specific deficiency of the 
AT1a receptors, has been found to decrease the incidence of AngII-induced ascending 
aortic aneurysms in hyperlipidemic mice.[89] However, the cell type responsible for 
AngII receptor expression contributing to AAA development has not been reported. This 
suggests that determining the specific cell type of the aorta that is responsible for the 
effects of COX-2 mediated AAA formation could be potentially important in further 
characterizing the mechanisms contributing to COX-2-dependent AAA formation in 
mice. Thus, future studies could be directed at utilizing the Cre-lox technology to 
generate mice deficient in COX-2 in specific cell types, such as endothelial cells or 
SMCs. These conditional COX-2 knockout mice could then be utilized to further define 
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the cell-specific role of COX-2, as well as the downstream PGs derived from COX-2, in 
AngII-induced AAA development. 
Our current studies suggest that COX-2 plays an important role in regulating the 
SMC phenotype during AngII-induced AAA development. However, the specific PGs 
responsible for modulating the SMC phenotype during AAA formation have thus far not 
been described. With in vitro studies suggesting conflicting evidences about the varied 
effects of different PGs on SMC phenotype, further studies are required to define the role 
of PGs in regulating SMC differentiation in vitro.[208, 209, 216]  
The expression of COX-2 and resultant PGE2 production has been shown to be 
induced in aneurysmal tissue, as compared to the normal aorta.[4] Genetic deficiency of 
microsomal prostaglandin E synthase-1 (mPGES-1), which contributes to PGE2 synthesis 
downstream of COX-2, has also been reported to reduce AngII-induced AAA formation 
in mice.[163] However, although PGE2 has been shown to induce a de-differentiated 
SMC phenotype, the role of mPGES-1 in regulating SMC phenotype has not been 
described. Thus, future studies could be directed at utilizing pharmacological agents 
which inhibit mPGES-1 to determine the role of COX-2 derived PGE2 in regulating 
vascular SMC phenotype during AngII-induced AAA development in mice.  
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